amiodarone has been researched along with Ventricular Fibrillation in 452 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone and esmolol can help to prevent and treat post-cardiac surgery reperfusion ventricular fibrillation." | 9.69 | Comparison of amiodarone and esmolol for prevention of reperfusion ventricular fibrillation in individuals undergoing heart valve or aortic surgery: a study protocol for a randomized controlled clinical trial. ( Li, Y; Tian, AY; Wang, HN; Zhu, D, 2023) |
| "To investigate whether prophylactic amiodarone infusion prevents ventricular fibrillation after aortic cross-clamp release and attenuates cytokine production in patients with left ventricular hypertrophy undergoing cardiac surgery." | 9.30 | Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial. ( Kagaya, S; Kuroda, M; Mita, N; Miyoshi, S, 2019) |
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 9.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| "5 mg/kg, amiodarone 300 mg, or placebo before aortic crossclamp removal The primary outcomes were the incidence of ventricular fibrillation and the number of shocks required to terminate ventricular fibrillation." | 9.16 | Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: a randomized, double-blind, placebo-controlled trial. ( Abel, MD; Barbara, DW; Li, Z; Mauermann, WJ; Meade, LA; Pulido, JN; Schaff, HV; White, RD, 2012) |
| "The purpose of this study was to evaluate the efficacy of prophylactic single-dose amiodarone administered through the pump circuit before releasing the aortic cross-clamp (ACC) in preventing the occurrence of reperfusion ventricular fibrillation (RVF)." | 9.14 | Amiodarone for the prevention of reperfusion ventricular fibrillation. ( Chandra, A; Panigrahi, S; Samantaray, A, 2010) |
| "The frequency of occurrence of ventricular fibrillation was significantly higher in both the amiodarone (48%) and the control group (45%) as compared with the lidocaine group (20%) with no statistically significant difference between the amiodarone and the control groups." | 9.14 | Prophylactic amiodarone versus lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamp. ( Ayoub, CM; Azar, M; Bou-Khalil, P; El-Khatib, MF; Haddadin, AS; Harfouch, D; Nasr, VG; Sfeir, PM, 2009) |
| "In Japan, intravenous nifekalant (NIF) was often used for direct current cardioversion-resistant ventricular fibrillation (VF), until the use of intravenous amiodarone (AMD) was approved in 2007." | 9.14 | Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. ( Akieda, K; Amino, M; Fujibayashi, D; Fukushima, T; Hashida, T; Higami, S; Inokuchi, S; Kodama, I; Morita, S; Opthof, T; Otsuka, H; Shima, M; Tamura, K; Tanabe, T; Uemura, S; Yoshioka, K, 2010) |
| " A measure of the optimum regression residual (r(opt)) has been calculated, discriminating between post-myocardial infarction patients at high and low risk of arrhythmic death while on treatment with amiodarone." | 9.11 | Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. ( Caminal, P; de Luna, AB; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "The prophylactic effect of amiodarone on atrial fibrillation after coronary bypass grafting with extracorporeal circulation was compared with that of diltiazem in two groups of 60 patients each." | 9.11 | Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery. ( Bougioukas, G; Didilis, V; Konstantinou, F; Mikroulis, D; Tsakiridis, K; Vretzakis, G, 2005) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 9.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation." | 9.10 | Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. ( Barr, A; Cass, D; Cooper, R; Dorian, P; Gelaznikas, R; Schwartz, B, 2002) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 9.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| "The efficacy and the safety of amiodarone therapy in 82 patients with recurrent tachyarrhythmias, refractory to conventional antiarrhythmics, were evaluated by a multicenter trial." | 9.07 | Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias. ( Kato, K, 1992) |
| "To assess the most appropriate method of administering amiodarone and predicting its efficacy (empiric vs guided by Holter or by ventricular stimulation), 19 patients with sustained ventricular tachycardia or ventricular fibrillation underwent a "parallel study"." | 9.07 | [Treatment of malignant ventricular tachyarrhythmia with amiodarone: comparison of empirical administration and administration guided by Holter or ventricular stimulation. Results of the parallel test]. ( Bonso, A; D'Este, D; Delise, P; Di Pede, F; Gasparini, G; Piccolo, E; Raviele, A; Zanocco, A, 1991) |
| "The interaction between the efficacy and tolerance of amiodarone and the degree of left ventricular (LV) dysfunction was assessed in 126 patients with sustained ventricular tachyarrhythmias." | 9.06 | Development of congestive heart failure and alterations in left ventricular function in patients with sustained ventricular tachyarrhythmias treated with amiodarone. ( Brady, P; De Paola, AA; Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Spielman, SR, 1987) |
| "Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies." | 8.95 | Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. ( Chuma, M; Imai, T; Ishizawa, K; Izawa-Ishizawa, Y; Koga, T; Kondo, Y; Koyama, T; Kurata, Y; Nakura, H; Niimura, T; Sato, S; Sendo, T; Takechi, K; Tanaka, S; Zamami, Y, 2017) |
| "Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs." | 8.12 | Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest. ( Christenson, J; Davis, D; Daya, MR; Dorian, P; Grunau, B; Kudenchuk, P; Lane, DJ; Lupton, J; Okubo, M; Rea, T; Scheuermeyer, F; Vaillancourt, C; Wang, HE; Yannopoulos, D, 2022) |
| "In patients with hypertriglyceridemia, it may be necessary for clinicians to pay more attention to the clinical symptoms along with fluctuations in amiodarone levels and accordingly adjust amiodarone dosage." | 8.12 | Pharmacokinetics and pharmacodynamics of amiodarone in patients with hypertriglyceridemia: Two case reports. ( Hayakawa, N; Kusano, K; Mukai, Y; Noda, T; Sakakura, K; Takada, M; Uno, T, 2022) |
| " We included adult patients with shockable rhythms, such as ventricular fibrillation and pulseless ventricular tachycardia, who were administered either lidocaine or amiodarone." | 8.12 | Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry. ( Amagasa, S; Fukushima, F; Kashiura, M; Kishihara, Y; Moriya, T; Yasuda, H, 2022) |
| "International guidelines recommend amiodarone for out-of-hospital cardiac arrest (OHCA) in refractory ventricular fibrillation (VF)." | 8.02 | Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation. ( Bosley, E; Doan, TN; Rashford, S; Schultz, BV; Wilson, D; Wissa, J, 2021) |
| " ibutilide) on ventricular fibrillation (VF) and hemodynamic status in a canine heart failure (HF) model." | 7.96 | Ibutilide Reduces Ventricular Defibrillation Threshold and Organizes Ventricular Fibrillation Activation in Canine Heart Failure Model. ( Chen, K; Han, Y; Huang, S; Jin, Q; Lin, C; Luo, Q; Shen, W; Wei, Y; Wu, L; Zhang, N, 2020) |
| "To describe the successful management of ventricular fibrillation (VF) and ventricular tachycardia (VT) using cardiopulmonary resuscitation, including defibrillation, followed by continuous rate infusion of IV amiodarone, in a cat with cardiac arrest secondary to tachyarrhythmia." | 7.96 | Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. ( Berlin, N; Kelmer, E; Maiorkis, I; Ohad, DG, 2020) |
| "The 2015 AHA guidelines recommend that amiodarone should be used for patients with refractory ventricular fibrillation (RVF)." | 7.91 | Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data. ( Choi, HJ; Kim, G; Kim, YJ; Lee, CA; Lee, DK; Moon, HJ; Oh, J; Oh, YT; Park, SM; Yang, HC, 2019) |
| " Six hours later, he developed ventricular fibrillation and he was not responding to amiodarone infusion, and 4 times defibrillation and cardioversion." | 7.85 | Fatal butane toxicity and delayed onset of refractory ventricular fibrillation. ( Almulhim, KN, 2017) |
| "Selective late INa inhibition with eleclazine does not alter DFT50 or dominant frequency of ventricular fibrillation when administered alone or in combination with amiodarone." | 7.85 | The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation. ( Batatinha, JA; Belardinelli, L; Bonatti, R; Nearing, BD; Silva, AF; Verrier, RL; Zeng, D, 2017) |
| "This nationwide study suggested no significant in-hospital mortality association between nifekalant and amiodarone for cardiogenic out-of-hospital cardiac arrest patients with ventricular fibrillation/persistent ventricular tachycardia on hospital arrival." | 7.83 | Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. ( Fukuda, R; Fushimi, K; Ishinokami, S; Kitahashi, A; Matsui, H; Oyanagi, M; Tagami, T; Unemoto, K; Yasunaga, H, 2016) |
| "The latest resuscitation guidelines recommend the use of amiodarone in adult patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (VF) to improve the rates of return of spontaneous circulation." | 7.83 | Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. ( Fushimi, K; Ishinokami, S; Kaneko, J; Kuno, M; Matsui, H; Tagami, T; Tanaka, C; Unemoto, K; Yasunaga, H, 2016) |
| "The purpose of the experiment was to compare the effects of nifekalant and amiodarone on the return of spontaneous circulation (ROSC), survival, as well as on the hemodynamic parameters in a swine model of prolonged ventricular fibrillation (VF)." | 7.81 | Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. ( Iacovidou, N; Karlis, G; Lelovas, P; Mentzelopoulos, S; Niforopoulou, P; Papalois, A; Siafaka, I; Xanthos, T, 2015) |
| "To determine the association between amiodarone and lidocaine and outcomes in children with cardiac arrest with pulseless ventricular tachycardia (pVT) and ventricular fibrillation (VF)." | 7.80 | Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. ( Berg, MD; Berg, RA; Donoghue, AJ; Hammond, R; Hoyme, DB; Samson, RA; Valdes, SO, 2014) |
| " Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks." | 7.80 | Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. ( Aibara, K; Goto, K; Harayama, N; Isa, Y; Kamochi, M; Nagata, K; Nihei, S; Sata, T, 2014) |
| "To compare the early postarrest inflammatory cytokine response between animals administered amiodarone (AMIO) and lidocaine (LIDO) intra-arrest during resuscitation from ventricular fibrillation (VF)." | 7.79 | Administration of amiodarone during resuscitation is associated with higher tumor necrosis factor-α levels in the early postarrest period in the swine model of ischemic ventricular fibrillation. ( Niemann, JT; Rosborough, JP; Shah, AP; Thomas, JL; Youngquist, ST, 2013) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 7.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "The effects of amiodarone on ventricular electrophysiological parameters, especially the dispersion of ventricular repolarization, were investigated in a canine model of congestive heart failure (CHF)." | 7.78 | Effect of amiodarone on dispersion of ventricular repolarization in a canine congestive heart failure model. ( Fang, C; Lei, J; Wang, JF; Zhang, YL; Zheng, SX; Zhou, SX, 2012) |
| "Nurses noted that the rate of phlebitis was high when intravenous amiodarone was infused via a peripheral site." | 7.78 | Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone. ( Boyce, BA; Yee, BH, 2012) |
| "Amiodarone is widely used in Europe and the United States for refractory ventricular fibrillation (VF) in various situations, such as VF after myocardial infarction or out-of-hospital cardiac arrest." | 7.76 | [Successful use of intravenous amiodarone for refractory ventricular fibrillation just after releasing aortic cross-clamp]. ( Iwasaki, T; Kanazawa, T; Matsuoka, M; Morimatsu, H; Morita, K; Shimizu, K; Suemori, T; Suzuki, S; Toda, Y; Yokoi, N, 2010) |
| "The effects of dronedarone, a non-iodinated derivative of amiodarone, on ventricular tachycardia and ventricular fibrillation post-myocardial infarction are not well established." | 7.74 | Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Korantzopoulos, P; Pantos, C; Tsalikakis, DG, 2007) |
| "Amiodarone, which is generally classified as class III antiarrhythmic drug in the Vaughan Williams classification, is widely used for the treatments of refractory arrhythmias." | 7.73 | Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs. ( Chen, J; Hashimoto, K; Nagasawa, Y, 2005) |
| "Amiodarone is a powerful antiarrhythmic drug; however, its use may be complicated by thyrotoxicosis." | 7.73 | Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. ( Bertagna, X; Bertherat, J; Duboc, D; Guignat, L; Meune, C; Mouly, S; Thomopoulos, P; Uzan, L; Weber, S, 2006) |
| "Amiodarone has been shown to be superior to both placebo and lidocaine in improving survival to hospital admission for victims of out-of-hospital refractory ventricular fibrillation." | 7.72 | Effect of amiodarone on haemodynamics during cardiopulmonary resuscitation in a canine model of resistant ventricular fibrillation. ( Berg, RA; Cardoso, LF; Kern, KB; Paiva, EF; Perondi, MB; Ramirez, JA; Timerman, S, 2003) |
| "The effects of acute amiodarone infusion on dynamics of ventricular fibrillation (VF) are unclear." | 7.71 | Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle. ( Chang, CM; Chen, PS; Garfinkel, A; Karagueuzian, HS; Lee, MH; Lin, SF; Naik, A; Omichi, C; Weiss, JN; Zhou, S, 2002) |
| "The goal of this study was to evaluate the effects of acute and chronic amiodarone on activation patterns during ventricular fibrillation (VF), ventricular effective refractory period (VERP) and defibrillation threshold (DFT)." | 7.71 | The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. ( Holman, WL; Huang, J; Ideker, RE; Rogers, JM; Skinner, JL; Smith, WM, 2002) |
| "To study the effects of amiodarone (Ami) on cardiac electrophysiologic properties and ventricular fibrillation threshold (VFT) in right ventricular rapid pacing-induced congestive heart failure (CHF) dogs." | 7.70 | Effects of amiodarone on cardiac electrophysiology in right ventricular rapid pacing-induced heart failure dogs. ( Chen, XC; Wu, W; Zhang, XM; Zhou, SX, 1998) |
| " Large doses of catecholamines given during resuscitation, in the presence of butane, may cause recurrent ventricular fibrillation." | 7.70 | Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. ( Edwards, KE; Wenstone, R, 2000) |
| "A comparative study on ventricular electrophysiologic effects of experimental hypothyroidism and chronic oral amiodarone administration was made in canine models, with the application of electrical stimulation and monophasic action potential recording." | 7.69 | Comparison of cardiac electrophysiologic effects of experimental hypothyroidism and chronic oral amiodarone administration in dogs. ( Li, JM; Liu, PM; Tang, Y; Wu, W; Zhang, XM, 1994) |
| "The aim of this study was to evaluate the efficacy of a single dose of intravenous amiodarone in facilitating defibrillation of ventricular fibrillation refractory to lidocaine and epinephrine plus direct current countershocks in experimental acute myocardial infarction." | 7.69 | Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. ( Anastasiou-Nana, MI; Moulopoulos, SD; Nanas, JN; Nanas, SN; Poyadjis, A; Rapti, A; Stathaki, S, 1994) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 7.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 7.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| "In 22 anesthetized mongrel dogs, spectral methods were used to analyze the surface electrocardiogram (ECG) for the time course of the dominant frequency in ventricular fibrillation and its modifications under the influence of amiodarone, diltiazem, and flecainide." | 7.69 | Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study. ( Bataller, M; Chorro, FJ; Cortina, J; Espí, J; Guerrero, J; López-Merino, V; Ruipérez, JA; Sánchez-Muñoz, JJ; Sanchis, J, 1996) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 7.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| "One hundred twenty-two patients treated chronically with amiodarone for sustained ventricular tachycardia or ventricular fibrillation after failing conventional antiarrhythmic therapy were analyzed to determine which factors were predictive of sudden cardiac death during follow-up." | 7.68 | Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. ( Foster, JR; Olson, PJ; Simpson, RJ; Woelfel, A, 1993) |
| "A group of 34 consecutive patients with coronary artery disease (n = 29) or dilated cardiomyopathy (n = 5) (3 women, 31 men, age 38-80 yr) who had severely impaired left ventricular function (left ventricular ejection fraction less than or equal to 40%) and high-grade ventricular ectopic activity (sustained or nonsustained ventricular tachycardia or ventricular fibrillation) were treated with amiodarone (mean dose: 206 mg/d) and followed for 1-117 (mean: 49) months." | 7.68 | Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction. ( Burckhardt, D; Hoffmann, A; Pfisterer, M; Robertson, A, 1991) |
| "The relationship between the antiarrhythmic effect of amiodarone and its myocardial concentration was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia or ventricular fibrillation." | 7.68 | Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF; Jimmo, S, 1991) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 7.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| " Recently, amiodarone has been shown to be rapidly effective in suppressing sustained, incessant ventricular tachycardia and ventricular fibrillation in this setting." | 7.68 | Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs. ( Horrigan, TP; Mostow, ND; Noon, DL; Rosalion, A; Snow, NJ, 1991) |
| "Our experience with amiodarone therapy in 145 consecutively referred patients with medically refractory sustained ventricular tachycardia and/or fibrillation treated for at least 3 years was reviewed." | 7.68 | Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. ( Gang, ES; Mandel, WJ; Myers, M; Nalos, PC; Oseran, DS; Peter, T; Weiss, D, 1990) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 7.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| ") amiodarone infusion (10 to 20 mg/kg/day for 4 to 7 days) followed by chronic oral amiodarone therapy (400 to 800 mg/day for 24 to 53 days) were evaluated in 17 patients with refractory sustained ventricular tachycardia (VT) or ventricular fibrillation." | 7.67 | Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. ( Cappello, G; Rothbart, ST; Saksena, S; Shah, Y, 1984) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 7.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients." | 7.67 | Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. ( Harringer, W; Herbinger, W; Kerschner, K; Leisch, F; Schützenberger, W, 1989) |
| "A 41-year-old male patient developed amiodarone-induced thyrotoxicosis after 29 months of treatment with amiodarone." | 7.67 | Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis. ( Weissel, M, 1988) |
| "Induction of ventricular tachycardia (VT) at electrophysiologic study in patients taking amiodarone poorly predicts recurrence of VT." | 7.67 | Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop ( Chang, MS; Fineberg, N; Heger, JJ; Kammerling, JM; Klein, LS; Miles, WM; Prystowsky, EN; Zipes, DP, 1988) |
| "The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT)." | 7.67 | Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent. ( Felder, SD; Figura, I; Fisher, JD; Johnston, DR; Kim, SG; Mercando, AD, 1987) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 7.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "Fifty-four patients with a previous myocardial infarction and drug-refractory symptomatic ventricular tachycardia (VT) were treated with amiodarone on a long-term basis (range 6 to 54 months, mean 26) irrespective of the results of programmed ventricular stimulation, which was performed after high-dose oral amiodarone loading for more than 4 weeks." | 7.67 | Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. ( Alpert, JS; Bishop, RL; Gold, RL; Haffajee, CI; Yazaki, Y, 1987) |
| "The main goal of this project was to study the effect of amiodarone upon ventricular fibrillation and defibrillation thresholds (VFT and VDT) in the canine heart under normal and ischemic conditions." | 7.67 | Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. ( Arredondo, MT; Guillen, SG; Quinteiro, RA, 1986) |
| "Several studies have reported upon the inducibility of ventricular tachycardia (VT) with programmed ventricular stimulation (PVS) during chronic amiodarone therapy; however, few studies have systematically described and compared the morphology, duration, and cycle length of VT induced by PVS before and after amiodarone." | 7.67 | Effects of chronic amiodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation. ( Annesley, T; Baerman, JM; de Buitleir, M; DiCarlo, LA; Morady, F; Schurig, L, 1987) |
| "We examined the value of clinical variables, chronic 24-hour ambulatory ECG monitoring, and chronic electrophysiologic (EP) testing in 49 patients with recurrent and refractory sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) treated with chronic oral amiodarone in order to develop a prospective approach to the management of these patients." | 7.67 | Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal. ( Lavery, D; Saksena, S, 1987) |
| "Over a 10-year period 130 patients with drug-resistant cardiac arrhythmias associated mainly with coronary artery disease and its complications were treated with amiodarone." | 7.67 | Amiodarone for refractory cardiac arrhythmias: 10-year study. ( Eydt, JN; Leak, D, 1986) |
| "The prognostic importance of electrophysiologic studies in patients with sustained ventricular tachyarrhythmias treated with amiodarone was prospectively studied in 100 consecutive patients." | 7.67 | Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. ( Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Rae, AP; Rotmensch, H; Segal, BL; Sokoloff, NM; Spielman, SR; Webb, CR, 1985) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 7.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "Seventy-four patients with sustained ventricular tachyarrhythmias had 22 +/- 3 hours of Holter monitoring before and after 11 +/- 6 days of amiodarone treatment." | 7.67 | Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. ( Buxton, AE; Doherty, JU; Flores, BT; Josephson, ME; Marchlinski, FE; Waxman, HL, 1985) |
| "Intravenous amiodarone has a clear anti-arrhythmic effect on induced sustained ventricular tachycardia (VT) in pigs with subacute myocardial infarction." | 7.67 | [Effect of amiodarone on stimulatory convertibility and degeneration into ventricular fibrillation of induced ventricular tachycardias in the pig]. ( Gertsch, M; Hottinger, S; Leupi, F; Mettler, D, 1985) |
| "Fifty-eight patients with symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF) were treated with amiodarone." | 7.66 | Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. ( Hess, DS; Morady, F; Scheinman, MM, 1983) |
| "Amiodarone was used in 40 patients with life-threatening or refractory tachyarrhythmias." | 7.66 | Amiodarone therapy for life threatening or refractory cardiac arrhythmias. ( Anderson, ST; Currie, PJ; Federman, J; Harper, RW; Johns, JA; Pitt, A, 1983) |
| "The clinical antiarrhythmic efficacy of amiodarone treatment was examined in 196 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) resistant to other antiarrhythmic drugs." | 7.66 | Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. ( Heger, JJ; Prystowsky, EN; Zipes, DP, 1983) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 7.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Ninety-six patients with recurrent, drug-refractory tachyarrhythmias were treated with amiodarone for 8." | 7.66 | Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. ( Anderson, KP; Fogoros, RN; Mason, JW; Swerdlow, CD; Winkle, RA, 1983) |
| "Amiodarone, 600 mg orally daily, was used in an attempt to control supraventricular tachyarrhythmias in a patient with the sick sinus syndrome." | 7.66 | Amiodarone-induced ventricular fibrillation. ( Adgey, AA; Geddes, JS; Khan, MM; Logan, KR; McComb, JM, 1980) |
| "The pretreatment of rats with amiodarone for 2 minutes to 3 weeks before the excision of their hearts caused a dose-related decrease in heart rate and an increase in the ventricular fibrillation threshold both before and after coronary arterial ligation." | 7.66 | Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart. ( Lubbe, WF; McFadyen, ML; Muller, CA; Opie, LH; Worthington, M, 1979) |
| "Ventricular fibrillation is common after aortic declamping in patients undergoing open heart surgery." | 6.79 | The effect of lidocaine and amiodarone on prevention of ventricular fibrillation in patients undergoing coronary artery bypass grafting. ( Arslan, ZI; Ata, Y; Aydin, U; Balcı, C; Kocogullari, CU; Turk, T; Yilmaz, M, 2014) |
| "Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients)." | 6.69 | Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. ( Cobb, LA; Copass, MK; Cummins, RO; Doherty, AM; Fahrenbruch, CE; Hallstrom, AP; Kudenchuk, PJ; Murray, WA; Olsufka, M; Walsh, T, 1999) |
| "Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter." | 6.68 | Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995) |
| "Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy and safety." | 6.46 | Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. ( Dorian, P; Van Herendael, H, 2010) |
| "Eighty-four cases of ventricular arrhythmia-induced shock and ROSC (return of spontaneous circulation) were divided into the prior amiodarone or β-blockers use group (Aβ group, n = 27) and the non-amiodarone and non-β-blockers use group (non-Aβ group; n = 57) based on treatment before the onset of those arrhythmias." | 5.62 | Prognostic benefits of prior amiodarone or β-blocker use before the onset of ventricular arrhythmia with hemodynamic collapse. ( Nagao, K; Tachibana, E; Ueki, Y; Yamasaki, M; Yokoyama, M; Yonemoto, N; Yoshie, K, 2021) |
| "Background The effects of amiodarone and lidocaine on the return of spontaneous circulation (ROSC) in relation to time to treatment in patients with out-of-hospital cardiac arrest is not known." | 5.51 | Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shock-Refractory Out-of-Hospital Cardiac Arrest. ( Cheskes, S; Dorian, P; Lebovic, G; Lin, S; Rahimi, M, 2022) |
| "Amiodarone treatment prolonged RR intervals, reduced dispersion of action potential duration in the infarcted area and mean number of ectopic beats." | 5.51 | Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model. ( Jabbari, R; Jespersen, T; Lubberding, AF; Sattler, SM; Skibsbye, L; Tfelt-Hansen, J; Wakili, R, 2019) |
| "Bretylium was removed from Advanced Cardiac Life Support guidelines, and, to date, efficacy of amiodarone in hypothermia is unknown." | 5.32 | Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. ( Ehlers, J; Martin, G; O'Mara, K; Stoner, J; Tomlanovich, M, 2003) |
| "To investigate whether prophylactic amiodarone infusion prevents ventricular fibrillation after aortic cross-clamp release and attenuates cytokine production in patients with left ventricular hypertrophy undergoing cardiac surgery." | 5.30 | Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial. ( Kagaya, S; Kuroda, M; Mita, N; Miyoshi, S, 2019) |
| "Ventricular fibrillation was induced by pacing the right ventricle using a primary drive train at a cycle length of 270 msec for 8 beats." | 5.30 | The effect of amiodarone on the ventricular fibrillation threshold. ( Chen, BP; Chow, MS; Fan, C; Kluger, J; White, CM, 1999) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 5.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Amiodarone was discontinued because of side effects in 14%, 26% and 37% of patients after 1, 3 and 5 years, respectively." | 5.28 | Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. ( Goldberg, H; Griffin, JC; Helmy, I; Herre, JM; Langberg, JJ; Malone, P; Sauve, MJ; Scheinman, MM, 1989) |
| " It also has antiarrhythmic properties and may thus be an alternative to amiodarone for the treatment of ventricular fibrillation (VF)." | 5.24 | Dantrolene versus amiodarone for cardiopulmonary resuscitation: a randomized, double-blinded experimental study. ( Dersch, W; Eschbach, D; Feldmann, C; Freitag, D; Irqsusi, M; Steinfeldt, T; Wiesmann, T; Wulf, H, 2017) |
| "The aim of the study was to systematically review evidence on the effectiveness and safety of oral mexiletine administered in monotherapy or in combination with other antiarrhythmic drugs for recurrent ventricular arrhythmia (ventricular tachycardia/ventricular fibrillation, VT/VF) in adult patients with structural heart disease (SHD) and implantable cardioverter defibrillators (ICDs)." | 5.22 | Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review. ( Anic, A; Boveda, S; Conte, G; de Asmundis, C; Farkowski, MM; Karlinski, M; Lewandowski, M; Marijon, E; Mugnai, G; Providencia, R; Pytkowski, M, 2022) |
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 5.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| "Amiodarone therapy, especially chronic, can result in difficult ventricular fibrillation (VF) inductions during implantable cardioverter defibrillator (ICD) testing." | 5.17 | Effectiveness of VF induction with DC fibber versus conventional induction methods in patients on chronic amiodarone therapy. ( Gupta, MS; Kim, MH; Rubenstein, JC, 2013) |
| "The purpose of this study was to evaluate the efficacy of prophylactic single-dose amiodarone administered through the pump circuit before releasing the aortic cross-clamp (ACC) in preventing the occurrence of reperfusion ventricular fibrillation (RVF)." | 5.14 | Amiodarone for the prevention of reperfusion ventricular fibrillation. ( Chandra, A; Panigrahi, S; Samantaray, A, 2010) |
| "In Japan, intravenous nifekalant (NIF) was often used for direct current cardioversion-resistant ventricular fibrillation (VF), until the use of intravenous amiodarone (AMD) was approved in 2007." | 5.14 | Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. ( Akieda, K; Amino, M; Fujibayashi, D; Fukushima, T; Hashida, T; Higami, S; Inokuchi, S; Kodama, I; Morita, S; Opthof, T; Otsuka, H; Shima, M; Tamura, K; Tanabe, T; Uemura, S; Yoshioka, K, 2010) |
| " A measure of the optimum regression residual (r(opt)) has been calculated, discriminating between post-myocardial infarction patients at high and low risk of arrhythmic death while on treatment with amiodarone." | 5.11 | Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. ( Caminal, P; de Luna, AB; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "The prophylactic effect of amiodarone on atrial fibrillation after coronary bypass grafting with extracorporeal circulation was compared with that of diltiazem in two groups of 60 patients each." | 5.11 | Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery. ( Bougioukas, G; Didilis, V; Konstantinou, F; Mikroulis, D; Tsakiridis, K; Vretzakis, G, 2005) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 5.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation." | 5.10 | Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. ( Barr, A; Cass, D; Cooper, R; Dorian, P; Gelaznikas, R; Schwartz, B, 2002) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 5.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| "The Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) study evaluated antiarrhythmic drug therapy in patients who had survived an episode of out-of-hospital ventricular fibrillation (VF) and who were thought to be at high risk for recurrence of VF." | 5.07 | The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. ( Greene, HL, 1993) |
| "The Cardiac Arrest in Seattle, Conventional Versus Amiodarone Drug Evaluation (CASCADE) study evaluated antiarrhythmic drug therapy in high-risk survivors of out-of-hospital ventricular fibrillation." | 5.07 | Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. ( Dolack, GL, 1994) |
| "The Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) study evaluated antiarrhythmic drug treatment of survivors of out-of-hospital ventricular fibrillation (VF) not associated with a Q-wave myocardial infarction who were at especially high risk of recurrence of VF." | 5.07 | Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. ( , 1993) |
| "The efficacy and the safety of amiodarone therapy in 82 patients with recurrent tachyarrhythmias, refractory to conventional antiarrhythmics, were evaluated by a multicenter trial." | 5.07 | Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias. ( Kato, K, 1992) |
| "The effects of two regimens for the initiation of amiodarone therapy were compared in 92 patients with inducible sustained ventricular tachycardia (VT) at baseline electrophysiologic testing." | 5.07 | A comparison of standard and high-dose regimens for the initiation of amiodarone therapy. ( Kadish, A; Morady, F; Summitt, J, 1992) |
| "The effects of long-term amiodarone therapy on the defibrillation thresholds and the rate of shocks were evaluated in 62 patients who had implantation of an automatic cardioverter-defibrillator (n = 53) or prophylactic implantation of patch electrodes (n = 9) who were survivors of sudden cardiac death (n = 34) or had refractory rapid ventricular tachycardia (n = 28)." | 5.07 | Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. ( Chenarides, JG; Huang, SK; Okike, NO; Tan de Guzman, WL; Vander Salm, TJ, 1991) |
| "To assess the most appropriate method of administering amiodarone and predicting its efficacy (empiric vs guided by Holter or by ventricular stimulation), 19 patients with sustained ventricular tachycardia or ventricular fibrillation underwent a "parallel study"." | 5.07 | [Treatment of malignant ventricular tachyarrhythmia with amiodarone: comparison of empirical administration and administration guided by Holter or ventricular stimulation. Results of the parallel test]. ( Bonso, A; D'Este, D; Delise, P; Di Pede, F; Gasparini, G; Piccolo, E; Raviele, A; Zanocco, A, 1991) |
| "The interaction between the efficacy and tolerance of amiodarone and the degree of left ventricular (LV) dysfunction was assessed in 126 patients with sustained ventricular tachyarrhythmias." | 5.06 | Development of congestive heart failure and alterations in left ventricular function in patients with sustained ventricular tachyarrhythmias treated with amiodarone. ( Brady, P; De Paola, AA; Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Spielman, SR, 1987) |
| "Amiodarone, administered orally in doses of 200 to 600 mg/day, was remarkably effective in the treatment and prevention of a wide variety of atrial and ventricular arrhythmias." | 5.04 | Clinical efficacy of amiodarone as an antiarrhythmic agent. ( Chiale, PA; Elizari, MV; Halpern, MS; Lázzari, JO; Levi, RJ; Nau, GJ; Przybylski, J; Rosenbaum, MB, 1976) |
| "Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies." | 4.95 | Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. ( Chuma, M; Imai, T; Ishizawa, K; Izawa-Ishizawa, Y; Koga, T; Kondo, Y; Koyama, T; Kurata, Y; Nakura, H; Niimura, T; Sato, S; Sendo, T; Takechi, K; Tanaka, S; Zamami, Y, 2017) |
| "We identified three articles addressing lidocaine versus amiodarone in cardiac arrest: 1) a prospective study assessing lidocaine versus amiodarone for refractory ventricular fibrillation in out-of-hospital adults; 2) an observational retrospective cohort study of inpatient pediatric patients with ventricular fibrillation or pulseless ventricular tachycardia who received lidocaine, amiodarone, neither or both; and 3) a prospective study of ventricular tachycardia with a pulse in adults." | 4.95 | Amiodarone Versus Lidocaine for Pediatric Cardiac Arrest Due to Ventricular Arrhythmias: A Systematic Review. ( Atkins, DL; De Caen, AR; Lopez-Herce, J; Marino, BS; McBride, ME; Webster, G; Ziegler, CP, 2017) |
| "Decades after its registration, amiodarone is still regarded as the most effective antiarrhythmic drug available for the treatment of tachyarrhythmias." | 4.86 | [Current role of amiodarone in antiarrhythmic therapy]. ( Sohns, C; Zabel, M, 2010) |
| "Biphasic defibrillation and intravenous amiodarone are useful in shock-resistant ventricular fibrillation." | 4.82 | Strategies for reversing shock-resistant ventricular fibrillation. ( Dorian, P; Sarkozy, A, 2003) |
| " A second prospective, randomized clinical trial of amiodarone for refractory ventricular fibrillation has again shown positive results in improving survival to hospital admission." | 4.82 | Cardiopulmonary Resuscitation Guidelines 2000 update: what's happened since? ( Kern, KB; Xavier, LC, 2003) |
| " Amiodarone can effectively prevent and control postoperative atrial and ventricular fibrillation." | 4.82 | Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. ( Drewe, J; Krähenbühl, S; Pargger, H; Rätz Bravo, AE; Schlienger, RG; Ummenhofer, W, 2005) |
| " For patients who have a history of sustained ventricular tachycardia(VT) or ventricular fibrillation(VF) amiodarone or an implantable cardioverter defibrillator(ICD) should be considered, and these therapy may benefit some high risk patients who have nonsustained VT." | 4.81 | [Heart failure]. ( Komuro, I; Yonezawa, M, 2002) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular rhythm disturbances." | 4.81 | Amiodarone: an emergency medicine perspective. ( Taylor, SE, 2002) |
| " In patients with a history of resuscitated ventricular fibrillation (VF) or unstable ventricular tachycardia (VT), the ICD was superior to therapy with amiodarone in 3 large trials involving 2,024 patients." | 4.80 | Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation. ( Hohnloser, SH, 1999) |
| "Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias." | 4.80 | Amiodarone: clinical trials. ( Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000) |
| "Amiodarone is a new antiarrhythmic drug approved for therapy of life-threatening ventricular tachycardia and ventricular fibrillation refractory to previous antiarrhythmic therapy." | 4.77 | Practical follow-up guidelines for patients treated with amiodarone. ( Podrid, PJ, 1987) |
| "American Heart Association Advanced Cardiac Life Support (ACLS) guidelines support the use of either amiodarone or lidocaine for cardiac arrest caused by ventricular tachycardia or ventricular fibrillation (VT/VF) based on studies of out-of-hospital cardiac arrest." | 4.31 | Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest. ( Bradley, SM; Cranford, JA; Kronick, SL; Nawer, H; Neumar, RW; Wagner, D, 2023) |
| "Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs." | 4.12 | Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest. ( Christenson, J; Davis, D; Daya, MR; Dorian, P; Grunau, B; Kudenchuk, P; Lane, DJ; Lupton, J; Okubo, M; Rea, T; Scheuermeyer, F; Vaillancourt, C; Wang, HE; Yannopoulos, D, 2022) |
| "In patients with hypertriglyceridemia, it may be necessary for clinicians to pay more attention to the clinical symptoms along with fluctuations in amiodarone levels and accordingly adjust amiodarone dosage." | 4.12 | Pharmacokinetics and pharmacodynamics of amiodarone in patients with hypertriglyceridemia: Two case reports. ( Hayakawa, N; Kusano, K; Mukai, Y; Noda, T; Sakakura, K; Takada, M; Uno, T, 2022) |
| " We included adult patients with shockable rhythms, such as ventricular fibrillation and pulseless ventricular tachycardia, who were administered either lidocaine or amiodarone." | 4.12 | Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry. ( Amagasa, S; Fukushima, F; Kashiura, M; Kishihara, Y; Moriya, T; Yasuda, H, 2022) |
| "We enrolled all consecutive patients with unsuccessful/not feasible catheter ablation and ineffective/contraindicated amiodarone or beta-blockers, which started the mexiletine treatment for refractory ventricular tachycardia (VT) or ventricular fibrillation (VF) between January 2010 and January 2020." | 4.12 | Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study. ( Bilato, C; Cavedon, S; Mecenero, A; Mugnai, G; Paolini, C; Perrone, C, 2022) |
| "International guidelines recommend amiodarone for out-of-hospital cardiac arrest (OHCA) in refractory ventricular fibrillation (VF)." | 4.02 | Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation. ( Bosley, E; Doan, TN; Rashford, S; Schultz, BV; Wilson, D; Wissa, J, 2021) |
| "We retrospectively evaluated survival in 160 consecutive adults with refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest treated with the University of Minnesota (UMN) ECPR protocol (transport with ongoing cardiopulmonary resuscitation [CPR] to the cardiac catheterization laboratory for ECPR) compared with 654 adults who had received standard CPR in the amiodarone arm of the ALPS trial (Amiodarone, Lidocaine, or Placebo Study)." | 3.96 | Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated With Prolonged Resuscitation. ( Aufderheide, TP; Bartos, JA; Carlson, C; Conterato, M; Duval, S; Frascone, RJ; Grunau, B; John, R; Kalra, R; Raveendran, G; Ripeckyj, A; Trembley, A; Yannopoulos, D, 2020) |
| " ibutilide) on ventricular fibrillation (VF) and hemodynamic status in a canine heart failure (HF) model." | 3.96 | Ibutilide Reduces Ventricular Defibrillation Threshold and Organizes Ventricular Fibrillation Activation in Canine Heart Failure Model. ( Chen, K; Han, Y; Huang, S; Jin, Q; Lin, C; Luo, Q; Shen, W; Wei, Y; Wu, L; Zhang, N, 2020) |
| "To describe the successful management of ventricular fibrillation (VF) and ventricular tachycardia (VT) using cardiopulmonary resuscitation, including defibrillation, followed by continuous rate infusion of IV amiodarone, in a cat with cardiac arrest secondary to tachyarrhythmia." | 3.96 | Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. ( Berlin, N; Kelmer, E; Maiorkis, I; Ohad, DG, 2020) |
| "To determine the association between amiodarone or lidocaine and outcomes in adult in-hospital cardiac arrest (IHCA) with shock-refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT)." | 3.96 | Outcomes associated with amiodarone and lidocaine for the treatment of adult in-hospital cardiac arrest with shock-refractory pulseless ventricular tachyarrhythmia. ( Chang, WT; Chen, WJ; Huang, CH; Liu, YB; Tsai, MS; Wang, CH; Wu, YW; Yu, PH, 2020) |
| "The 2015 AHA guidelines recommend that amiodarone should be used for patients with refractory ventricular fibrillation (RVF)." | 3.91 | Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data. ( Choi, HJ; Kim, G; Kim, YJ; Lee, CA; Lee, DK; Moon, HJ; Oh, J; Oh, YT; Park, SM; Yang, HC, 2019) |
| " Six hours later, he developed ventricular fibrillation and he was not responding to amiodarone infusion, and 4 times defibrillation and cardioversion." | 3.85 | Fatal butane toxicity and delayed onset of refractory ventricular fibrillation. ( Almulhim, KN, 2017) |
| "This nationwide study suggested no significant in-hospital mortality association between nifekalant and amiodarone for cardiogenic out-of-hospital cardiac arrest patients with ventricular fibrillation/persistent ventricular tachycardia on hospital arrival." | 3.83 | Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. ( Fukuda, R; Fushimi, K; Ishinokami, S; Kitahashi, A; Matsui, H; Oyanagi, M; Tagami, T; Unemoto, K; Yasunaga, H, 2016) |
| "The purpose of the experiment was to compare the effects of nifekalant and amiodarone on the return of spontaneous circulation (ROSC), survival, as well as on the hemodynamic parameters in a swine model of prolonged ventricular fibrillation (VF)." | 3.81 | Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. ( Iacovidou, N; Karlis, G; Lelovas, P; Mentzelopoulos, S; Niforopoulou, P; Papalois, A; Siafaka, I; Xanthos, T, 2015) |
| "To determine the association between amiodarone and lidocaine and outcomes in children with cardiac arrest with pulseless ventricular tachycardia (pVT) and ventricular fibrillation (VF)." | 3.80 | Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. ( Berg, MD; Berg, RA; Donoghue, AJ; Hammond, R; Hoyme, DB; Samson, RA; Valdes, SO, 2014) |
| " Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks." | 3.80 | Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. ( Aibara, K; Goto, K; Harayama, N; Isa, Y; Kamochi, M; Nagata, K; Nihei, S; Sata, T, 2014) |
| " A year later, he developed thyrotoxicosis, presumably secondary to amiodarone administered for ventricular fibrillation." | 3.79 | Thyrotoxicosis-facilitated bridge to recovery with a continuous-flow left ventricular assist device. ( Frazier, OH; Letsou, GV; Reverdin, S, 2013) |
| "To compare the early postarrest inflammatory cytokine response between animals administered amiodarone (AMIO) and lidocaine (LIDO) intra-arrest during resuscitation from ventricular fibrillation (VF)." | 3.79 | Administration of amiodarone during resuscitation is associated with higher tumor necrosis factor-α levels in the early postarrest period in the swine model of ischemic ventricular fibrillation. ( Niemann, JT; Rosborough, JP; Shah, AP; Thomas, JL; Youngquist, ST, 2013) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 3.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "The effects of amiodarone on ventricular electrophysiological parameters, especially the dispersion of ventricular repolarization, were investigated in a canine model of congestive heart failure (CHF)." | 3.78 | Effect of amiodarone on dispersion of ventricular repolarization in a canine congestive heart failure model. ( Fang, C; Lei, J; Wang, JF; Zhang, YL; Zheng, SX; Zhou, SX, 2012) |
| "Nurses noted that the rate of phlebitis was high when intravenous amiodarone was infused via a peripheral site." | 3.78 | Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone. ( Boyce, BA; Yee, BH, 2012) |
| "We conducted a retrospective analysis of ST-segment elevation myocardial infarction patients with sustained ventricular tachycardia/ventricular fibrillation in Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB and GUSTO III and compared all-cause death in patients receiving amiodarone, lidocaine, or no antiarrhythmic." | 3.77 | Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. ( Alexander, JH; Ardissino, D; Califf, RM; Granger, CB; Mehta, RH; Ohman, EM; Piccini, JP; Pieper, KS; Schulte, PJ; Van de Werf, F; White, HD, 2011) |
| "Amiodarone is a potent antiarrhythmic agent with little if any negative inotropic effect and, therefore, is the agent of choice in patients with heart failure." | 3.77 | Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint. ( Lévy, S, 1994) |
| "After 4min of untreated ventricular fibrillation, animals were randomly treated with nifekalant (2mgkg(-1)), amiodarone (5mgkg(-1)) or saline placebo (n=12 pigs per group)." | 3.76 | Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. ( Cong, LH; Ji, XF; Li, CS; Wang, S; Yang, L, 2010) |
| "Amiodarone is widely used in Europe and the United States for refractory ventricular fibrillation (VF) in various situations, such as VF after myocardial infarction or out-of-hospital cardiac arrest." | 3.76 | [Successful use of intravenous amiodarone for refractory ventricular fibrillation just after releasing aortic cross-clamp]. ( Iwasaki, T; Kanazawa, T; Matsuoka, M; Morimatsu, H; Morita, K; Shimizu, K; Suemori, T; Suzuki, S; Toda, Y; Yokoi, N, 2010) |
| "The effects of dronedarone, a non-iodinated derivative of amiodarone, on ventricular tachycardia and ventricular fibrillation post-myocardial infarction are not well established." | 3.74 | Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Korantzopoulos, P; Pantos, C; Tsalikakis, DG, 2007) |
| "Amiodarone, which is generally classified as class III antiarrhythmic drug in the Vaughan Williams classification, is widely used for the treatments of refractory arrhythmias." | 3.73 | Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs. ( Chen, J; Hashimoto, K; Nagasawa, Y, 2005) |
| "Amiodarone is a powerful antiarrhythmic drug; however, its use may be complicated by thyrotoxicosis." | 3.73 | Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. ( Bertagna, X; Bertherat, J; Duboc, D; Guignat, L; Meune, C; Mouly, S; Thomopoulos, P; Uzan, L; Weber, S, 2006) |
| " Suddenly on the 6th day of the so far uncomplicated AMI ventricular fibrillation developed and was successfully treated with DC shock, and amiodarone (150 mg i." | 3.73 | [Polymorphic ventricular tachycardia in acute myocardial infarction without ST elevation in a patient with thrombocytopenia]. ( Bromblik, A; Bryniarski, L; Czamara, M; Dragan, J; Kukla, P; Szczuka, K; Słowiak-Lewińska, T, 2006) |
| "Amiodarone has been shown to be superior to both placebo and lidocaine in improving survival to hospital admission for victims of out-of-hospital refractory ventricular fibrillation." | 3.72 | Effect of amiodarone on haemodynamics during cardiopulmonary resuscitation in a canine model of resistant ventricular fibrillation. ( Berg, RA; Cardoso, LF; Kern, KB; Paiva, EF; Perondi, MB; Ramirez, JA; Timerman, S, 2003) |
| "Experimental studies have described an increase in ventricular fibrillation threshold (VFT) by intravenous amiodarone." | 3.72 | Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone--an experimental study. ( Anastasiou-Nana, MI; Charitos, CE; Doufas, A; Drakos, SG; Mavrikakis, EM; Nanas, JN; Ntalianis, A; Siafakas, CX; Terrovitis, JV; Tsagalou, EP, 2004) |
| "Although chronic amiodarone has been proven to be effective to suppress ventricular tachycardia (VT) and ventricular fibrillation (VF), how we predict the recurrence of VT/VF after chronic amiodarone remains unknown." | 3.72 | Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. ( Aiba, T; Aihara, N; Inagaki, M; Kamakura, S; Kurita, T; Satomi, K; Shimizu, W; Sunagawa, K; Suyama, K; Taguchi, A, 2004) |
| "The aim of this study was to evaluate the survival of patients with hypertrophic cardiomyopathy (HCM) after resuscitated ventricular fibrillation or syncopal sustained ventricular tachycardia (VT/VF) when treated with low dose amiodarone or implantable cardioverter defibrillators (ICDs)." | 3.70 | Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. ( Elliott, PM; McKenna, WJ; Poloniecki, J; Rowland, E; Sharma, S; Varnava, A, 1999) |
| "To study the effects of amiodarone (Ami) on cardiac electrophysiologic properties and ventricular fibrillation threshold (VFT) in right ventricular rapid pacing-induced congestive heart failure (CHF) dogs." | 3.70 | Effects of amiodarone on cardiac electrophysiology in right ventricular rapid pacing-induced heart failure dogs. ( Chen, XC; Wu, W; Zhang, XM; Zhou, SX, 1998) |
| "We evaluated the effect of two different doses of desethylamiodarone (DEA) and amiodarone on the ventricular fibrillation threshold (VFT)." | 3.70 | A comparison of the antifibrillatory effects of desethylamiodarone to amiodarone in a swine model. ( Chen, BP; Chow, MS; Fan, C; Kluger, J; White, CM; Zhou, L, 1999) |
| " Large doses of catecholamines given during resuscitation, in the presence of butane, may cause recurrent ventricular fibrillation." | 3.70 | Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. ( Edwards, KE; Wenstone, R, 2000) |
| "A comparative study on ventricular electrophysiologic effects of experimental hypothyroidism and chronic oral amiodarone administration was made in canine models, with the application of electrical stimulation and monophasic action potential recording." | 3.69 | Comparison of cardiac electrophysiologic effects of experimental hypothyroidism and chronic oral amiodarone administration in dogs. ( Li, JM; Liu, PM; Tang, Y; Wu, W; Zhang, XM, 1994) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "The aim of this study was to evaluate the efficacy of a single dose of intravenous amiodarone in facilitating defibrillation of ventricular fibrillation refractory to lidocaine and epinephrine plus direct current countershocks in experimental acute myocardial infarction." | 3.69 | Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. ( Anastasiou-Nana, MI; Moulopoulos, SD; Nanas, JN; Nanas, SN; Poyadjis, A; Rapti, A; Stathaki, S, 1994) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 3.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 3.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| " Data also suggest that amiodarone appears to be the safest antiarrhythmic drug for treatment sustained and nonsustained arrhythmias, and improved survival in patients with advanced heart failure." | 3.69 | [Pharmacologic treatment for ventricular arrhythmias]. ( Halawa, B, 1997) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 3.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| " "Conventional" antiarrhythmic agents, which primarily block cardiac sodium channels, are relatively ineffective in preventing arrhythmia recurrence; amiodarone and sotalol appear to be effective in reducing recurrence and mortality rates, although the extent of benefit is not well understood." | 3.68 | The implantable defibrillator and antiarrhythmic drugs--competitive and complementary treatment for severe ventricular arrhythmia. ( Dorian, P; Newman, D, 1993) |
| " The patient was discharged with digitalis, nitrates, aspirin and amiodarone for prophylactic treatment of paroxystic atrial fibrillation." | 3.68 | [Ventricular fibrillation during stress test on a treadmill. Apropos of a case]. ( Baroffio, R; Croce, A; Tisi, G, 1993) |
| "One hundred twenty-two patients treated chronically with amiodarone for sustained ventricular tachycardia or ventricular fibrillation after failing conventional antiarrhythmic therapy were analyzed to determine which factors were predictive of sudden cardiac death during follow-up." | 3.68 | Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. ( Foster, JR; Olson, PJ; Simpson, RJ; Woelfel, A, 1993) |
| "A potentially fatal arrhythmia was encountered in a patient with a previous myocardial infarction, who was resistant to treatment with lidocaine, amiodarone and electric defibrillation." | 3.68 | Stabilization of cardiac rhythm in subsequently fatal ventricular tachycardia and fibrillation by calcitonin gene-related peptide. ( Liu, J; Liu, XZ; Zhang, JF, 1992) |
| "A group of 34 consecutive patients with coronary artery disease (n = 29) or dilated cardiomyopathy (n = 5) (3 women, 31 men, age 38-80 yr) who had severely impaired left ventricular function (left ventricular ejection fraction less than or equal to 40%) and high-grade ventricular ectopic activity (sustained or nonsustained ventricular tachycardia or ventricular fibrillation) were treated with amiodarone (mean dose: 206 mg/d) and followed for 1-117 (mean: 49) months." | 3.68 | Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction. ( Burckhardt, D; Hoffmann, A; Pfisterer, M; Robertson, A, 1991) |
| "The relationship between the antiarrhythmic effect of amiodarone and its myocardial concentration was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia or ventricular fibrillation." | 3.68 | Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF; Jimmo, S, 1991) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 3.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| " Recently, amiodarone has been shown to be rapidly effective in suppressing sustained, incessant ventricular tachycardia and ventricular fibrillation in this setting." | 3.68 | Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs. ( Horrigan, TP; Mostow, ND; Noon, DL; Rosalion, A; Snow, NJ, 1991) |
| "Our experience with amiodarone therapy in 145 consecutively referred patients with medically refractory sustained ventricular tachycardia and/or fibrillation treated for at least 3 years was reviewed." | 3.68 | Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. ( Gang, ES; Mandel, WJ; Myers, M; Nalos, PC; Oseran, DS; Peter, T; Weiss, D, 1990) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 3.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| ") amiodarone infusion (10 to 20 mg/kg/day for 4 to 7 days) followed by chronic oral amiodarone therapy (400 to 800 mg/day for 24 to 53 days) were evaluated in 17 patients with refractory sustained ventricular tachycardia (VT) or ventricular fibrillation." | 3.67 | Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. ( Cappello, G; Rothbart, ST; Saksena, S; Shah, Y, 1984) |
| "The relationship of apparent steady-state serum concentrations of amiodarone and its metabolite, desethylamiodarone, to therapeutic and toxic effects was assessed in 127 patients who had treatment-resistant ventricular or supraventricular arrhythmias or were intolerant to other agents." | 3.67 | Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. ( Belhassen, B; Greenspan, AM; Greenspon, AJ; Horowitz, LN; Rotmensch, HH; Shoshani, D; Spielman, SR; Swanson, BN; Vlasses, PH, 1984) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 3.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients." | 3.67 | Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. ( Harringer, W; Herbinger, W; Kerschner, K; Leisch, F; Schützenberger, W, 1989) |
| "This study examined the effectiveness of intravenous amiodarone for rapid control and prevention of recurrent life-threatening ventricular tachyarrhythmias associated with cardiovascular collapse." | 3.67 | Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease. ( Almquist, A; Benditt, DG; Gobel, FL; Goldenberg, IF; Milstein, S; Ochi, RP; Pedersen, W; Pritzker, M, 1989) |
| "A 41-year-old male patient developed amiodarone-induced thyrotoxicosis after 29 months of treatment with amiodarone." | 3.67 | Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis. ( Weissel, M, 1988) |
| "Induction of ventricular tachycardia (VT) at electrophysiologic study in patients taking amiodarone poorly predicts recurrence of VT." | 3.67 | Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop ( Chang, MS; Fineberg, N; Heger, JJ; Kammerling, JM; Klein, LS; Miles, WM; Prystowsky, EN; Zipes, DP, 1988) |
| "The prognostic value of 3 previously reported programmed stimulation efficacy criteria was studied in 70 patients taking amiodarone for sustained ventricular tachycardia (VT)." | 3.67 | Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent. ( Felder, SD; Figura, I; Fisher, JD; Johnston, DR; Kim, SG; Mercando, AD, 1987) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 3.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "Fifty-four patients with a previous myocardial infarction and drug-refractory symptomatic ventricular tachycardia (VT) were treated with amiodarone on a long-term basis (range 6 to 54 months, mean 26) irrespective of the results of programmed ventricular stimulation, which was performed after high-dose oral amiodarone loading for more than 4 weeks." | 3.67 | Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. ( Alpert, JS; Bishop, RL; Gold, RL; Haffajee, CI; Yazaki, Y, 1987) |
| "The main goal of this project was to study the effect of amiodarone upon ventricular fibrillation and defibrillation thresholds (VFT and VDT) in the canine heart under normal and ischemic conditions." | 3.67 | Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. ( Arredondo, MT; Guillen, SG; Quinteiro, RA, 1986) |
| "Several studies have reported upon the inducibility of ventricular tachycardia (VT) with programmed ventricular stimulation (PVS) during chronic amiodarone therapy; however, few studies have systematically described and compared the morphology, duration, and cycle length of VT induced by PVS before and after amiodarone." | 3.67 | Effects of chronic amiodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation. ( Annesley, T; Baerman, JM; de Buitleir, M; DiCarlo, LA; Morady, F; Schurig, L, 1987) |
| "We examined the value of clinical variables, chronic 24-hour ambulatory ECG monitoring, and chronic electrophysiologic (EP) testing in 49 patients with recurrent and refractory sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) treated with chronic oral amiodarone in order to develop a prospective approach to the management of these patients." | 3.67 | Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal. ( Lavery, D; Saksena, S, 1987) |
| "Over a 10-year period 130 patients with drug-resistant cardiac arrhythmias associated mainly with coronary artery disease and its complications were treated with amiodarone." | 3.67 | Amiodarone for refractory cardiac arrhythmias: 10-year study. ( Eydt, JN; Leak, D, 1986) |
| "The prognostic importance of electrophysiologic studies in patients with sustained ventricular tachyarrhythmias treated with amiodarone was prospectively studied in 100 consecutive patients." | 3.67 | Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. ( Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Rae, AP; Rotmensch, H; Segal, BL; Sokoloff, NM; Spielman, SR; Webb, CR, 1985) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 3.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "Seventy-four patients with sustained ventricular tachyarrhythmias had 22 +/- 3 hours of Holter monitoring before and after 11 +/- 6 days of amiodarone treatment." | 3.67 | Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. ( Buxton, AE; Doherty, JU; Flores, BT; Josephson, ME; Marchlinski, FE; Waxman, HL, 1985) |
| "Intravenous amiodarone has a clear anti-arrhythmic effect on induced sustained ventricular tachycardia (VT) in pigs with subacute myocardial infarction." | 3.67 | [Effect of amiodarone on stimulatory convertibility and degeneration into ventricular fibrillation of induced ventricular tachycardias in the pig]. ( Gertsch, M; Hottinger, S; Leupi, F; Mettler, D, 1985) |
| "Fifty-eight patients with symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF) were treated with amiodarone." | 3.66 | Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. ( Hess, DS; Morady, F; Scheinman, MM, 1983) |
| "Amiodarone was used in 40 patients with life-threatening or refractory tachyarrhythmias." | 3.66 | Amiodarone therapy for life threatening or refractory cardiac arrhythmias. ( Anderson, ST; Currie, PJ; Federman, J; Harper, RW; Johns, JA; Pitt, A, 1983) |
| "The clinical utility of electrophysiologic testing in assessing the long-term efficacy of amiodarone for treatment of life-threatening ventricular arrhythmias is controversial, most investigators reporting little or no correlation between the early effects of the drug on arrhythmia inducibility and subsequent prognosis." | 3.66 | Ventricular arrhythmias: use of electrophysiologic studies. ( Greenspan, AM; Horowitz, LN; Kay, HR; Spielman, SR; Webb, CR, 1983) |
| "The clinical antiarrhythmic efficacy of amiodarone treatment was examined in 196 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) resistant to other antiarrhythmic drugs." | 3.66 | Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. ( Heger, JJ; Prystowsky, EN; Zipes, DP, 1983) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 3.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation." | 3.66 | Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. ( Heger, JJ; Jackman, WM; Naccarelli, GV; Prystowsky, EN; Rinkenberger, RL; Warfel, KA; Zipes, DP, 1981) |
| "Ninety-six patients with recurrent, drug-refractory tachyarrhythmias were treated with amiodarone for 8." | 3.66 | Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. ( Anderson, KP; Fogoros, RN; Mason, JW; Swerdlow, CD; Winkle, RA, 1983) |
| "Amiodarone, 600 mg orally daily, was used in an attempt to control supraventricular tachyarrhythmias in a patient with the sick sinus syndrome." | 3.66 | Amiodarone-induced ventricular fibrillation. ( Adgey, AA; Geddes, JS; Khan, MM; Logan, KR; McComb, JM, 1980) |
| "The pretreatment of rats with amiodarone for 2 minutes to 3 weeks before the excision of their hearts caused a dose-related decrease in heart rate and an increase in the ventricular fibrillation threshold both before and after coronary arterial ligation." | 3.66 | Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart. ( Lubbe, WF; McFadyen, ML; Muller, CA; Opie, LH; Worthington, M, 1979) |
| "A long Q-T interval syndrome is described, followed by "torsade de pointe" and by irriducible ventricular fibrillation that is ascribed to a badly conducted therapy with amiodarone, in a patient affected by mitral valve disease, microcitaemia and hemolitic intercurrent moderate jaundice." | 3.66 | ["T'orsade de pointe" and amiodarone (author's transl)]. ( Guerricchio, G; Scandiffio, T; Veglia, L, 1978) |
| " Group A contained patients demonstrating amiodarone lung toxicity diagnosed by chest X-ray, KL-6 or D(LCO) (n=6), whereas group B included patients treated without any adverse effects (n=20)." | 2.74 | Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance. ( Harada, M; Hiramatsu, S; Kuruma, T; Maruyama, T; Odashiro, K; Yasuda, S; Yasuda, Y, 2009) |
| "An intravenous bolus injection and subsequent continuous infusion of NIF at a relatively low dosage were effective in treating severe ventricular tachyarrhythmias complicating ACS, reducing the potential risk of proarrhythmia." | 2.74 | Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. ( Abe, A; Ikeda, T; Ishiguro, H; Mera, H; Miwa, Y; Miyakoshi, M; Shimizu, H; Tsukada, T; Yoshino, H; Yusu, S, 2009) |
| "Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients)." | 2.69 | Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. ( Cobb, LA; Copass, MK; Cummins, RO; Doherty, AM; Fahrenbruch, CE; Hallstrom, AP; Kudenchuk, PJ; Murray, WA; Olsufka, M; Walsh, T, 1999) |
| "Most studies of cardiac arrest report outcome following out-of-hospital resuscitation." | 2.69 | In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. ( Cannom, DS; Epstein, AE; Greene, HL; Herre, JM; Lancaster, S; Ocampo, C; Powell, J; Rosenberg, Y; Yao, Q, 1999) |
| " Thus, in these patients, the speed and dosing accuracy of an intravenous formulation would be beneficial." | 2.68 | Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. ( Cannom, DS; Chilson, DA; Friehling, T; Kopelman, HA; Kowey, PR; Levine, JH; Platia, EV; Scheinman, MM; Wilber, DJ, 1995) |
| "Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter." | 2.68 | Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995) |
| " However, there was no clear dose-response relation observed in this trial with respect to success rates (primary end point), time to first recurrence of tachyarrhythmia (post hoc analysis) or mortality (secondary end point) over 24 h." | 2.68 | Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. ( Chilson, DA; Gomes, A; Levine, JH; Massumi, A; Platia, EV; Scheinman, MM; Winkle, RA; Woosley, RL, 1996) |
| " It was concluded that the pharmacokinetic parameters of amiodarone in these patients were similar to those reported for healthy volunteers and were similarly variable." | 2.68 | Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. ( Chiang, ST; de Vane, PJ; Korth-Bradley, JM; Peters, J; Rose, GM, 1996) |
| "Patients with ventricular tachycardia also had either syncope or other serious cardiac symptoms, along with a left ventricular ejection fraction of 0." | 2.68 | A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. ( , 1997) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "Ventricular fibrillation was induced with AC (applied for 1-2 seconds), and standard epicardial bipolar and epicardial patch electrodes of the AICD were used for pacing and defibrillation, respectively." | 2.67 | Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation. ( Aarons, D; Juanteguy, J; Khastgir, T; Lattuca, J; Murphy, J; O'Mara, V; Veltri, EP, 1991) |
| "Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy and safety." | 2.46 | Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. ( Dorian, P; Van Herendael, H, 2010) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "The short QT syndrome has been recently recognised as a genetic ion channel dysfunction." | 2.43 | Short QT syndrome: a case report and review of literature. ( Cao, Q; Lu, LX; Yu, K; Zhang, X; Zhou, W; Zhu, C, 2006) |
| "Recurrent sustained ventricular tachycardia and ventricular fibrillation in the acute phase after cardiac surgery is the most lethal arrhythmia and may warrant acute intervention and aggressive treatment." | 2.41 | [Management of lethal ventricular arrhythmias after cardiac surgery]. ( Ohnishi, S, 2002) |
| "A wide spectrum of ventricular and supraventricular tachyarrhythmias occurs in the setting of congestive cardiac failure." | 2.41 | Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. ( Singh, BN, 2002) |
| "In patients with asymptomatic ventricular tachyarrhythmias in heart failure, class I antiarrhythmic drugs should be avoided due to proarrhythmic and negative inotropic effects that may be responsible for increased mortality in some trials." | 2.41 | [Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias]. ( Kasanuki, H; Ohnishi, S, 2000) |
| "Patients with sustained ventricular tachyarrhythmias in the absence of a reversible cause require long-term therapy." | 2.40 | Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. ( Mitchell, LB, 1997) |
| " The studies that were reviewed were selected on the basis of time published (from 1983 to 1995) and the completeness of information provided regarding patient clinical characteristics, drug dosing and methods of evaluation, efficacy analyses, long-term follow-up and complications." | 2.40 | Intravenous amiodarone. ( Filart, RA; Kowey, PR; Marinchak, RA; Rials, SJ, 1997) |
| "Amiodarone was introduced as an antiarrhythmic compound in the early 1970s and was approved in the U." | 2.40 | Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. ( Singh, BN, 1997) |
| "Patients with symptomatic ventricular tachycardia, ventricular fibrillation, or aborted sudden cardiac death remain at high risk for arrhythmia recurrence." | 2.40 | Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. ( Borggrefe, M; Breithardt, G; Eckardt, L; Haverkamp, W, 1997) |
| "In addition to primary prevention of ventricular tachycardia and supraventricular tachycardia, antiarrhythmic drug therapy may potentiate tachycardia rate slowing and make ventricular tachycardia more tolerated hemodynamically and possibly more amendable to pacing therapy." | 2.40 | Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions. ( Ashar, M; Deely, MP; Marchlinski, FE; Nayak, H; Saligan, J; Zado, ES, 1999) |
| "Pharmacological therapy of cardiac arrhythmias continues to evolve, with an increasing shift from class I to class III compounds and beta-blockers." | 2.39 | Class III antiarrhythmic drugs. ( Ahmed, R; Singh, BN, 1994) |
| "sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing." | 2.39 | [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Haverkamp, W, 1996) |
| "Amiodarone is a viable drug for preventing sudden cardiac death, particularly during the first year after MI." | 2.38 | Amiodarone and post-MI patients. ( Nademanee, K; Singh, BN; Stevenson, WG; Weiss, JN, 1993) |
| "Amiodarone has been shown to both increase and decrease the DFT." | 2.38 | Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place? ( McCollam, PL; Nappi, JM, 1993) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | 2.38 | Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. ( Anderson, JL, 1990) |
| "Awake patients in ventricular fibrillation is a phenomenon limited to patients who are mechanically supported." | 1.91 | Stable Ventricular Fibrillation: A Paradigm Rather Than Septal Shift? ( Bracy, CL; Gupta, R; Hockstein, MA; Hockstein, MJ; Kobres, PY; Lam, PH; Rao, SD; Sheikh, FH, 2023) |
| "Eighty-four cases of ventricular arrhythmia-induced shock and ROSC (return of spontaneous circulation) were divided into the prior amiodarone or β-blockers use group (Aβ group, n = 27) and the non-amiodarone and non-β-blockers use group (non-Aβ group; n = 57) based on treatment before the onset of those arrhythmias." | 1.62 | Prognostic benefits of prior amiodarone or β-blocker use before the onset of ventricular arrhythmia with hemodynamic collapse. ( Nagao, K; Tachibana, E; Ueki, Y; Yamasaki, M; Yokoyama, M; Yonemoto, N; Yoshie, K, 2021) |
| "Amiodarone was continued as an outpatient." | 1.62 | Asymptomatic ventricular fibrillation in continuous flow left-ventricular assist device. ( Moak, JH; Smith, ME, 2021) |
| "Amiodarone treatment prolonged RR intervals, reduced dispersion of action potential duration in the infarcted area and mean number of ectopic beats." | 1.51 | Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model. ( Jabbari, R; Jespersen, T; Lubberding, AF; Sattler, SM; Skibsbye, L; Tfelt-Hansen, J; Wakili, R, 2019) |
| "Polymorphic ventricular tachycardia (VT) without QT prolongation is well described in patients without structural heart disease (mainly idiopathic ventricular fibrillation and Brugada syndrome) and in patients with acute ST-elevation myocardial infarction." | 1.51 | Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. ( Amit, G; Asher, E; Belhassen, B; Chorin, E; Halkin, A; Havakuk, O; Hochstadt, A; Laish-Farkash, A; Lee, JK; Rosso, R; Tovia-Brodie, O; Viskin, D; Viskin, S, 2019) |
| "Amiodarone was also used in 90% of the ICD group." | 1.40 | Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. ( Baggio, JM; Ferreira, LG; Gali, WL; Gomes, GG; Junqueira, LF; Marin-Neto, JA; Sarabanda, AV, 2014) |
| "Recent guidelines for treating ventricular fibrillation (VF) and ventricular tachycardia (VT) stress class III antiarrhythmic drugs, but some malignant arrhythmias refractory to these agents still occur in clinical practice." | 1.40 | Renewed impact of lidocaine on refractory ventricular arrhythmias in the amiodarone era. ( Ikeda, U; Miura, T; Motoki, H; Okada, A; Takeuchi, T; Tomita, T; Yoshie, K, 2014) |
| "The results suggest that pretreatment with saffron, especially at the dosage of 100 mg/kg/day, attenuates the susceptibility and incidence of fatal ventricular arrhythmia during the reperfusion period in the rat." | 1.39 | Protective effects of saffron (Crocus sativus) against lethal ventricular arrhythmias induced by heart reperfusion in rat: a potential anti-arrhythmic agent. ( Bashiri, A; Ghasemipour-Afshar, E; Joukar, S; Naghsh, N; Sheibani, M, 2013) |
| "Standardised test protocol for an NCS is safe in patients with an ICD regardless of the leads type." | 1.38 | Safety of nerve conduction studies in patients with implantable cardioverter-defibrillators. ( Antczak, J; Banach, M; Derejko, M; Derejko, P; Niewiadomska, M; Przybylski, A; Rakowicz, M; Szumowski, Ł; Walczak, F, 2012) |
| "Caffeine is a natural alkaloid methylxanthine that is found in various plants such as coffee or tea." | 1.36 | A case of fatal caffeine poisoning. ( Knudsen, K; Rudolph, T, 2010) |
| "Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2." | 1.35 | Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. ( Cannom, DS; Estes, NA; Glidden, DV; Marcus, F; Marcus, GM; Polonsky, B; Scheinman, MM; Smith, LM; Zareba, W, 2009) |
| "The patient presented with episodes of seizure-like activity, which were subsequently shown to be caused by ventricular fibrillation." | 1.34 | Varicella zoster induced cardiac dysfunction: a case report. ( Dennison, P; Zaremba, E, 2007) |
| "Polymorphic ventricular tachycardia (VT) comprises a variety of different subforms." | 1.33 | Amiodarone and polymorphic ventricular tachycardia: to slow down or to accelerate the underlying rhythm? ( Goethals, M; Pollet, P, 2006) |
| "Bretylium was removed from Advanced Cardiac Life Support guidelines, and, to date, efficacy of amiodarone in hypothermia is unknown." | 1.32 | Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. ( Ehlers, J; Martin, G; O'Mara, K; Stoner, J; Tomlanovich, M, 2003) |
| "Amiodarone (200 mg/day) was administered for 6 months and programmed ventricular stimulation was repeated." | 1.32 | Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient. ( Kanmatsuse, K; Kasamaki, Y; Kofune, T; Masaki, R; Ohkubo, K; Okumura, Y; Oshikawa, N; Ozawa, Y; Saito, S; Watanabe, I; Yamada, T, 2003) |
| "The most prevalent inclusion bradyarrhythmia was > or =second-degree AV block (82%)." | 1.32 | Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. ( Almendral, J; Arenal, A; Díaz-Castro, O; Martínez-Selles, M; Puchol, A; Torrecilla, EG, 2004) |
| "Recurrent ventricular fibrillation was observed in a 29-year-old Vietnamese man who did not exhibit structural heart disease." | 1.31 | Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? ( Kalla, H; Marinchak, R; Yan, GX, 2000) |
| "We report cases of serious arrhythmias associated with apical hypertrophic cardiomyopathy (AHCM)." | 1.31 | Serious arrhythmias in patients with apical hypertrophic cardiomyopathy. ( Azegami, K; Itoh, K; Okishige, K; Sasano, T; Suzuki, K; Yano, K, 2001) |
| "In patients with ischemic heart disease, recurrences of VT or VF peaked in the morning." | 1.31 | Absence of a morning peak in ventricular tachycardia and fibrillation events in nonischemic heart disease: analysis of therapies by implantable cardioverter defibrillators. ( Aizawa, Y; Taneda, K, 2001) |
| "An amiodarone infusion was started and continued over a period of 72 h." | 1.31 | Amiodarone used in successful resuscitation after near-fatal flecainide overdose. ( Board, PN; Siegers, A, 2002) |
| "Amiodarone treatment prolonged action-potential duration by 12." | 1.30 | Effects of long-term amiodarone treatment on ventricular-fibrillation vulnerability and defibrillation efficacy in response to monophasic and biphasic shocks. ( Behrens, S; Franz, MR; Li, C, 1997) |
| "Amiodarone was used as first line therapy or after failure of digoxin." | 1.30 | [Recommendations for the treatment of recurrent supraventricular tachycardia in infants]. ( Acar, P; Aggoun, Y; Bonnet, D; Kachaner, J; Sidi, D; Villain, E, 1998) |
| "In 8 patients paroxysmal atrial fibrillation (AF), in 2 patients chronic AF, in 1 patient atrial flutter, and in 3 patients sinus tachycardia triggered antitachycardia pacing functions (12 patients) or internal defibrillation (2 patients)." | 1.29 | Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators. ( Melichercik, J; Montero, M; Schmitt, C, 1994) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 1.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "We present a case with dilated cardiomyopathy and recurrent sustained monomorphic ventricular tachycardia who received an automatic implantable cardioverter defibrillator (AICD) while under long-term amiodarone treatment." | 1.29 | Is there an effect of amiodarone on the defibrillation threshold? ( Akalin, H; Akyol, T; Bayar, M; Güldal, M; Karaoguz, R, 1993) |
| "The increase in induced sustained ventricular tachycardia cycle length in group A patients after amiodarone loading was significantly correlated with the increase in VERP (r = ." | 1.29 | Frequency-dependent electrophysiologic effects of amiodarone in humans. ( Antimisiaris, M; Follmer, C; Pruitt, C; Sager, PT; Singh, BN; Uppal, P, 1993) |
| "Surprisingly, arrhythmia recurrence rates were not significantly different by the method of determining an efficacy prediction." | 1.29 | Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. ( Anderson, JL, 1995) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | 1.29 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996) |
| "Amiodarone was prescribed orally at degressive doses." | 1.29 | [Predictive factors of induction of ventricular arrhythmia under amiodarone]. ( Bellon, C; Bonnefoy, E; Bouchayer, D; Bourret, N; Chevalier, P; Kirkorian, G; Richalet, C; Touboul, P, 1996) |
| " A standardized oral loading dosage was used for all patients (1,200 mg/day for 14 days; 800 mg/day for 7 days; and 400 mg/day thereafter)." | 1.28 | Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. ( Duff, HJ; Gillis, AM; Mitchell, LB; Wyse, DG, 1989) |
| "Amiodarone was discontinued because of side effects in 14%, 26% and 37% of patients after 1, 3 and 5 years, respectively." | 1.28 | Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. ( Goldberg, H; Griffin, JC; Helmy, I; Herre, JM; Langberg, JJ; Malone, P; Sauve, MJ; Scheinman, MM, 1989) |
| " The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing." | 1.27 | [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation]. ( Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984) |
| "under AM therapy the initial arrhythmias were no longer detectable in 41% of the patients." | 1.27 | [Antiarrhythmic effect and side effects of amiodarone]. ( Haddad, R; Konrad, K; Mainitz, M; Mlczoch, J; Probst, P; Scheibelhofer, W; Weber, H; Weissel, M, 1984) |
| " Drug or metabolite concentrations in plasma and RBCs correlated directly with daily dosage of amiodarone." | 1.27 | Plasma and red blood cell concentrations of amiodarone during chronic therapy. ( Heger, JJ; Prystowsky, EN; Solow, EB; Zipes, DP, 1984) |
| "Amiodarone was therefore studied in 40 consecutive patients (with previous cardiac arrests) in whom conventional antiarrhythmic therapy had proved ineffective or was not tolerated." | 1.27 | Control of sudden recurrent arrhythmic deaths: role of amiodarone. ( Cannom, DS; Feld, G; Nademanee, K; Singh, BN; Stevenson, WG; Weiss, J, 1983) |
| "Sotalol was found to be effective therapy for a subset of patients with ventricular tachycardia unresponsive to type IA drugs." | 1.27 | Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. ( Gonzalez, R; Griffin, JC; Herre, JM; Sauve, MJ; Scheinman, MM; Sharkey, H, 1988) |
| "Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data." | 1.27 | Safety and efficacy of amiodarone. The low-dose perspective. ( Friehling, TD; Kowey, PR; Marinchak, RA; Stohler, JL; Sulpizi, AM, 1988) |
| "A patient with clinically silent mitral valve prolapse experienced an episode of out-of-hospital cardiac arrest due to ventricular fibrillation." | 1.27 | Ventricular fibrillation in a patient with 'silent' mitral valve prolapse. ( Agmon, J; Caspi, A; Kusniec, J; Lewin, RF; Sclarovsky, S; Strasberg, B, 1988) |
| "The effects of amiodarone on the pharmacokinetic and electrophysiologic properties of procainamide were examined in eight patients treated for recurrent ventricular arrhythmias who received intravenous procainamide, 6 to 15 mg/kg, at control and after 1 to 2 weeks of oral amiodarone treatment." | 1.27 | Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ( Heger, JJ; Miles, WM; Prystowsky, EN; Windle, J, 1987) |
| "Thirty-three patients treated with an abbreviated oral amiodarone loading regimen for ventricular tachycardia underwent electrophysiologic testing in the control state, after 1 week of high-dose (1170 +/- 88 mg/day) inpatient therapy; and after an 8-week intermediate (669 +/- 129 mg/day) dosing phase." | 1.27 | Dissociation of electrophysiologic and pharmacologic stability during an abbreviated oral loading regimen of amiodarone. ( Batsford, WP; Bookbinder, MJ; Kennedy, EE; McPherson, CA; Perlmutter, RA; Rosenfeld, LF, 1987) |
| " Minor reactions were defined as those that required dosage reduction and major reactions as those that required drug discontinuation or permanent pacing for bradycardia." | 1.27 | Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias. ( Cook, TS; DiMarco, JP; Nygaard, TW; Sellers, TD, 1986) |
| "Amiodarone therapy was initiated with a 5 mg/kg infusion followed by 600 to 800 mg/day for 7 to 10 days, then 200 to 400 mg/day." | 1.27 | Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity. ( Benaderet, D; Blevins, RD; Faitel, K; Garfinkel, C; Jarandilla, R; Kerin, NZ; Klein, S; Rubenfire, M, 1986) |
| "Amiodarone was given to 17 patients with drug refractory sustained ventricular arrhythmias." | 1.27 | Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effectiveness. ( Alpert, MA; Flaker, GC; Ruder, MA; Sanfelippo, JF; Tsutakawa, RK; Webel, RR, 1985) |
| "Amiodarone was without effect." | 1.26 | Comparative antidysrhythmic profiles of bepridil, amiodarone and disopyramide in the guinea-pig and dog. ( Basiez, M; Beaughard, M; Duchene-Marullaz, P; Labrid, C; Leinot, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (19.91) | 18.7374 |
| 1990's | 141 (31.19) | 18.2507 |
| 2000's | 98 (21.68) | 29.6817 |
| 2010's | 94 (20.80) | 24.3611 |
| 2020's | 29 (6.42) | 2.80 |
| Authors | Studies |
|---|---|
| Aleksandrowicz, D | 1 |
| Freire-Tellado, M | 1 |
| Navarro-Patón, R | 1 |
| Mateos-Lorenzo, J | 1 |
| Pérez-López, G | 1 |
| Pavón-Prieto, MDP | 1 |
| Lane, DJ | 1 |
| Grunau, B | 3 |
| Kudenchuk, P | 1 |
| Dorian, P | 18 |
| Wang, HE | 1 |
| Daya, MR | 1 |
| Lupton, J | 1 |
| Vaillancourt, C | 3 |
| Okubo, M | 1 |
| Davis, D | 1 |
| Rea, T | 3 |
| Yannopoulos, D | 2 |
| Christenson, J | 2 |
| Scheuermeyer, F | 1 |
| Rahimi, M | 1 |
| Cheskes, S | 2 |
| Lebovic, G | 1 |
| Lin, S | 1 |
| Farkowski, MM | 1 |
| Karlinski, M | 1 |
| Pytkowski, M | 1 |
| de Asmundis, C | 1 |
| Lewandowski, M | 1 |
| Mugnai, G | 2 |
| Conte, G | 1 |
| Marijon, E | 1 |
| Anic, A | 1 |
| Boveda, S | 1 |
| Providencia, R | 1 |
| Reiffel, JA | 2 |
| Uno, T | 1 |
| Sakakura, K | 1 |
| Mukai, Y | 1 |
| Takada, M | 1 |
| Noda, T | 1 |
| Kusano, K | 2 |
| Hayakawa, N | 1 |
| Wagner, D | 1 |
| Kronick, SL | 1 |
| Nawer, H | 1 |
| Cranford, JA | 1 |
| Bradley, SM | 1 |
| Neumar, RW | 1 |
| Kishihara, Y | 1 |
| Kashiura, M | 1 |
| Amagasa, S | 1 |
| Fukushima, F | 1 |
| Yasuda, H | 1 |
| Moriya, T | 1 |
| Spears, J | 1 |
| Kowey, P | 1 |
| Jouffroy, R | 1 |
| Ecollan, P | 1 |
| Chollet-Xemard, C | 1 |
| Prunet, B | 1 |
| Elie, C | 1 |
| Treluyer, JM | 1 |
| Vivien, B | 1 |
| Yetmiş, F | 1 |
| Babayigit, E | 1 |
| Görenek, B | 1 |
| Murphy, TW | 1 |
| Kadir, S | 1 |
| Bracy, CL | 1 |
| Kobres, PY | 1 |
| Hockstein, MJ | 1 |
| Rao, SD | 1 |
| Gupta, R | 1 |
| Lam, PH | 1 |
| Sheikh, FH | 1 |
| Hockstein, MA | 1 |
| Zhu, D | 1 |
| Li, Y | 1 |
| Tian, AY | 1 |
| Wang, HN | 1 |
| Rassi, FM | 1 |
| Minohara, L | 1 |
| Rassi, A | 2 |
| Correia, LCL | 1 |
| Marin-Neto, JA | 2 |
| da Silva Menezes, A | 1 |
| Lee, DK | 1 |
| Kim, YJ | 1 |
| Kim, G | 1 |
| Lee, CA | 1 |
| Moon, HJ | 1 |
| Oh, J | 1 |
| Yang, HC | 1 |
| Choi, HJ | 2 |
| Oh, YT | 1 |
| Park, SM | 1 |
| Bartos, JA | 1 |
| Carlson, C | 1 |
| Duval, S | 1 |
| Ripeckyj, A | 1 |
| Kalra, R | 1 |
| Raveendran, G | 1 |
| John, R | 1 |
| Conterato, M | 1 |
| Frascone, RJ | 1 |
| Trembley, A | 1 |
| Aufderheide, TP | 3 |
| Tijssen, J | 1 |
| DeCaen, A | 1 |
| Arias, MA | 1 |
| Pachón, M | 1 |
| Loughlin, G | 1 |
| Zhang, N | 2 |
| Luo, Q | 1 |
| Jin, Q | 2 |
| Han, Y | 1 |
| Huang, S | 1 |
| Wei, Y | 1 |
| Lin, C | 2 |
| Chen, K | 2 |
| Shen, W | 2 |
| Wu, L | 2 |
| Mott, IH | 1 |
| Poulsen, SH | 1 |
| Løgstrup, BB | 1 |
| Berlin, N | 1 |
| Ohad, DG | 1 |
| Maiorkis, I | 1 |
| Kelmer, E | 1 |
| Pravdin, SF | 1 |
| Epanchintsev, TI | 1 |
| Panfilov, AV | 1 |
| Yoshie, K | 2 |
| Yamasaki, M | 1 |
| Yokoyama, M | 1 |
| Ueki, Y | 1 |
| Tachibana, E | 1 |
| Yonemoto, N | 1 |
| Nagao, K | 1 |
| Noh, H | 1 |
| Paolini, C | 1 |
| Cavedon, S | 1 |
| Mecenero, A | 1 |
| Perrone, C | 1 |
| Bilato, C | 1 |
| Smith, ME | 1 |
| Moak, JH | 1 |
| Meyer-Szary, J | 1 |
| Gasecka, A | 1 |
| John, I | 1 |
| Jaguszewski, MJ | 1 |
| Peacock, FW | 1 |
| Gilis-Malinowska, N | 1 |
| Szarpak, L | 1 |
| Wissa, J | 1 |
| Schultz, BV | 1 |
| Wilson, D | 1 |
| Rashford, S | 1 |
| Bosley, E | 1 |
| Doan, TN | 1 |
| Tagami, T | 3 |
| Yasunaga, H | 3 |
| Yokota, H | 1 |
| Sato, S | 1 |
| Zamami, Y | 1 |
| Imai, T | 1 |
| Tanaka, S | 2 |
| Koyama, T | 1 |
| Niimura, T | 1 |
| Chuma, M | 1 |
| Koga, T | 1 |
| Takechi, K | 1 |
| Kurata, Y | 1 |
| Kondo, Y | 1 |
| Izawa-Ishizawa, Y | 1 |
| Sendo, T | 1 |
| Nakura, H | 1 |
| Ishizawa, K | 1 |
| Almulhim, KN | 1 |
| Kavakli, AS | 1 |
| Kavrut Ozturk, N | 1 |
| Salcido, DD | 1 |
| Schmicker, RH | 1 |
| Kime, N | 1 |
| Buick, JE | 1 |
| Zellner, S | 1 |
| Zive, D | 1 |
| Koller, AC | 1 |
| Herren, H | 1 |
| Nuttall, J | 1 |
| Sundermann, ML | 1 |
| Menegazzi, JJ | 1 |
| Mita, N | 1 |
| Kagaya, S | 1 |
| Miyoshi, S | 1 |
| Kuroda, M | 1 |
| Panchal, AR | 1 |
| Berg, KM | 1 |
| Kudenchuk, PJ | 8 |
| Del Rios, M | 1 |
| Hirsch, KG | 1 |
| Link, MS | 1 |
| Kurz, MC | 1 |
| Chan, PS | 1 |
| Cabañas, JG | 1 |
| Morley, PT | 1 |
| Hazinski, MF | 2 |
| Donnino, MW | 1 |
| Duff, JP | 1 |
| Topjian, A | 1 |
| Berg, MD | 2 |
| Chan, M | 1 |
| Haskell, SE | 1 |
| Joyner, BL | 1 |
| Lasa, JJ | 1 |
| Ley, SJ | 1 |
| Raymond, TT | 1 |
| Sutton, RM | 1 |
| Atkins, DL | 2 |
| Dalia, AA | 1 |
| Essandoh, MK | 1 |
| Sattler, SM | 1 |
| Lubberding, AF | 1 |
| Skibsbye, L | 1 |
| Jabbari, R | 1 |
| Wakili, R | 1 |
| Jespersen, T | 1 |
| Tfelt-Hansen, J | 1 |
| Viskin, S | 1 |
| Chorin, E | 1 |
| Viskin, D | 1 |
| Hochstadt, A | 1 |
| Halkin, A | 1 |
| Tovia-Brodie, O | 1 |
| Lee, JK | 1 |
| Asher, E | 1 |
| Laish-Farkash, A | 1 |
| Amit, G | 1 |
| Havakuk, O | 1 |
| Belhassen, B | 4 |
| Rosso, R | 1 |
| Beyranvand, MR | 1 |
| Farrokhi, S | 1 |
| Peyvandi, H | 1 |
| Soltaninejad, K | 1 |
| Shadnia, S | 1 |
| Wang, CH | 1 |
| Chang, WT | 1 |
| Huang, CH | 1 |
| Tsai, MS | 1 |
| Yu, PH | 1 |
| Wu, YW | 1 |
| Liu, YB | 1 |
| Chen, WJ | 1 |
| Letsou, GV | 1 |
| Reverdin, S | 1 |
| Frazier, OH | 1 |
| Krychtiuk, KA | 1 |
| Distelmaier, K | 1 |
| Pfaffenberger, S | 1 |
| Burger-Klepp, U | 1 |
| Niessner, A | 1 |
| Heinz, G | 1 |
| Speidl, WS | 1 |
| Riaz, A | 1 |
| Hieb, H | 1 |
| Foley, B | 1 |
| Mulvihill, N | 1 |
| Crean, P | 1 |
| Murphy, RT | 1 |
| Daly, C | 1 |
| Boyle, N | 1 |
| Glover, BM | 1 |
| Hu, X | 1 |
| Aves, T | 1 |
| Ramadeen, A | 1 |
| Zou, L | 1 |
| Leong-Poi, H | 1 |
| Fujii, H | 1 |
| Joukar, S | 1 |
| Ghasemipour-Afshar, E | 1 |
| Sheibani, M | 1 |
| Naghsh, N | 1 |
| Bashiri, A | 1 |
| Youngquist, ST | 1 |
| Niemann, JT | 1 |
| Shah, AP | 1 |
| Thomas, JL | 1 |
| Rosborough, JP | 1 |
| Li, T | 1 |
| Wei, X | 1 |
| Watkins, AC | 1 |
| Sanchez, PG | 1 |
| Wu, ZJ | 1 |
| Griffith, BP | 1 |
| Turker, I | 1 |
| Yu, CC | 1 |
| Chang, PC | 1 |
| Chen, Z | 1 |
| Sohma, Y | 1 |
| Lin, SF | 2 |
| Chen, PS | 2 |
| Ai, T | 1 |
| Rubenstein, JC | 1 |
| Gupta, MS | 1 |
| Kim, MH | 1 |
| Valdes, SO | 1 |
| Donoghue, AJ | 1 |
| Hoyme, DB | 1 |
| Hammond, R | 1 |
| Berg, RA | 2 |
| Samson, RA | 1 |
| Harayama, N | 2 |
| Nihei, S | 2 |
| Nagata, K | 2 |
| Isa, Y | 1 |
| Goto, K | 1 |
| Aibara, K | 2 |
| Kamochi, M | 2 |
| Sata, T | 2 |
| Gali, WL | 1 |
| Sarabanda, AV | 1 |
| Baggio, JM | 1 |
| Ferreira, LG | 1 |
| Gomes, GG | 1 |
| Junqueira, LF | 1 |
| Semenas, E | 2 |
| Sharma, HS | 1 |
| Wiklund, L | 1 |
| Brown, SP | 3 |
| Daya, M | 4 |
| Morrison, LJ | 3 |
| Grunau, BE | 1 |
| Aufderheide, T | 1 |
| Powell, J | 4 |
| Leroux, B | 3 |
| Larsen, J | 1 |
| Wittwer, L | 2 |
| Colella, MR | 2 |
| Stephens, SW | 1 |
| Gamber, M | 1 |
| Egan, D | 2 |
| Zoerner, F | 1 |
| Israel, CW | 2 |
| Manegold, JC | 1 |
| Kaese, S | 1 |
| Schülke, C | 1 |
| Lebiedz, P | 1 |
| Snipelisky, D | 1 |
| Roberts, M | 1 |
| Blackshear, J | 1 |
| Tomita, T | 1 |
| Takeuchi, T | 1 |
| Okada, A | 1 |
| Miura, T | 1 |
| Motoki, H | 1 |
| Ikeda, U | 1 |
| Iannone, P | 1 |
| Yilmaz, M | 1 |
| Aydin, U | 1 |
| Arslan, ZI | 1 |
| Balcı, C | 1 |
| Kocogullari, CU | 1 |
| Ata, Y | 1 |
| Turk, T | 1 |
| Fukuda, T | 1 |
| Nakamura, K | 1 |
| Fukuda-Ohashi, N | 1 |
| Yahagi, N | 1 |
| Frommeyer, G | 2 |
| Milberg, P | 2 |
| Schulze Grotthoff, J | 1 |
| Dechering, DG | 2 |
| Kochhäuser, S | 2 |
| Stypmann, J | 1 |
| Fehr, M | 1 |
| Breithardt, G | 7 |
| Eckardt, L | 4 |
| De Maria, E | 1 |
| Patrizi, G | 1 |
| Cappelli, S | 1 |
| Carmo, AA | 1 |
| Rocha, MO | 1 |
| Silva, JL | 1 |
| Ianni, BM | 1 |
| Fernandes, F | 1 |
| Sabino, EC | 1 |
| Ribeiro, AL | 1 |
| Karlis, G | 1 |
| Iacovidou, N | 1 |
| Lelovas, P | 1 |
| Niforopoulou, P | 1 |
| Papalois, A | 1 |
| Siafaka, I | 1 |
| Mentzelopoulos, S | 1 |
| Xanthos, T | 1 |
| Almotrefi, AA | 1 |
| Bukhari, IA | 1 |
| Alhumayyd, MS | 1 |
| Sarrias, A | 1 |
| Villuendas, R | 1 |
| Bisbal, F | 1 |
| Pereferrer, D | 1 |
| Rueda, F | 1 |
| Serra, J | 1 |
| García, C | 1 |
| Bayés-Genís, A | 1 |
| Merefield, DC | 1 |
| Beckham, J | 1 |
| Nichol, G | 1 |
| Callaway, CW | 1 |
| Ornato, JP | 1 |
| Weisfeldt, ML | 1 |
| Stiell, IG | 1 |
| Idris, AH | 1 |
| Dunford, JV | 1 |
| Vilke, GM | 1 |
| Brienza, AM | 1 |
| Desvigne-Nickens, P | 1 |
| Gray, PC | 1 |
| Gray, R | 1 |
| Seals, N | 1 |
| Straight, R | 1 |
| Chen, CY | 1 |
| Tsai, J | 1 |
| Hsu, TY | 1 |
| Lai, WY | 1 |
| Chen, WK | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Muraro, L | 1 |
| Longo, L | 1 |
| Geraldini, F | 1 |
| Bortot, A | 1 |
| Paoli, A | 1 |
| Boscolo, A | 1 |
| Ekström, K | 1 |
| Lehtonen, J | 1 |
| Kandolin, R | 1 |
| Räisänen-Sokolowski, A | 1 |
| Salmenkivi, K | 1 |
| Kupari, M | 1 |
| Pollak, PT | 1 |
| Spence, JD | 1 |
| Patel, JJ | 1 |
| Matsui, H | 2 |
| Ishinokami, S | 2 |
| Oyanagi, M | 1 |
| Kitahashi, A | 1 |
| Fukuda, R | 1 |
| Unemoto, K | 2 |
| Fushimi, K | 2 |
| Tanaka, C | 1 |
| Kaneko, J | 1 |
| Kuno, M | 1 |
| Rosini, JM | 1 |
| Zizza, L | 1 |
| Puckhaber, D | 1 |
| Ellermann, C | 1 |
| Leitz, P | 1 |
| Reinke, F | 1 |
| Gibson, AE | 1 |
| Jaeschke, R | 1 |
| Hunter, BR | 1 |
| Musey, PI | 1 |
| Bobbo, M | 1 |
| Pinamonti, B | 1 |
| Merlo, M | 1 |
| Stolfo, D | 1 |
| Iorio, A | 1 |
| Ramani, F | 1 |
| Barbati, G | 1 |
| Carriere, C | 1 |
| Massa, L | 1 |
| Poli, S | 1 |
| Scapol, S | 1 |
| Gigli, M | 1 |
| Di Lenarda, A | 1 |
| Sinagra, G | 1 |
| McBride, ME | 1 |
| Marino, BS | 1 |
| Webster, G | 1 |
| Lopez-Herce, J | 1 |
| Ziegler, CP | 1 |
| De Caen, AR | 1 |
| Silva, AF | 1 |
| Bonatti, R | 1 |
| Batatinha, JA | 1 |
| Nearing, BD | 1 |
| Zeng, D | 1 |
| Belardinelli, L | 1 |
| Verrier, RL | 1 |
| Wiesmann, T | 1 |
| Freitag, D | 1 |
| Dersch, W | 1 |
| Eschbach, D | 1 |
| Irqsusi, M | 1 |
| Steinfeldt, T | 1 |
| Wulf, H | 1 |
| Feldmann, C | 1 |
| O'Sullivan, M | 1 |
| Martinez, A | 1 |
| Long, A | 1 |
| Johnson, M | 1 |
| Blouin, D | 1 |
| Johnson, AD | 1 |
| Burgert, JM | 1 |
| Kuruma, T | 1 |
| Maruyama, T | 1 |
| Hiramatsu, S | 1 |
| Yasuda, Y | 1 |
| Yasuda, S | 1 |
| Odashiro, K | 1 |
| Harada, M | 1 |
| Blatt, JA | 1 |
| Poole, JE | 2 |
| Johnson, GW | 1 |
| Callans, DJ | 1 |
| Raitt, MH | 2 |
| Reddy, RK | 1 |
| Marchlinski, FE | 5 |
| Yee, R | 1 |
| Guarnieri, T | 2 |
| Talajic, M | 2 |
| Wilber, DJ | 3 |
| Anderson, J | 1 |
| Chung, K | 1 |
| Wong, WS | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 3 |
| Curtis, AB | 1 |
| Leeuwenburgh, BP | 1 |
| Versteegh, MI | 2 |
| Maas, JJ | 1 |
| Dunning, J | 1 |
| Maeda, K | 1 |
| Takagi, M | 1 |
| Tatsumi, H | 1 |
| Nakagawa, E | 1 |
| Yoshiyama, M | 1 |
| Tual, L | 1 |
| Sudrial, J | 1 |
| Marteau, A | 1 |
| Sebbah, JL | 1 |
| Dhonneur, G | 1 |
| Marcus, GM | 1 |
| Glidden, DV | 1 |
| Polonsky, B | 1 |
| Zareba, W | 1 |
| Smith, LM | 1 |
| Cannom, DS | 4 |
| Estes, NA | 1 |
| Marcus, F | 1 |
| Scheinman, MM | 12 |
| Mitchell, LB | 4 |
| Yusu, S | 1 |
| Ikeda, T | 1 |
| Mera, H | 1 |
| Miyakoshi, M | 1 |
| Miwa, Y | 1 |
| Abe, A | 1 |
| Tsukada, T | 1 |
| Ishiguro, H | 1 |
| Shimizu, H | 1 |
| Yoshino, H | 1 |
| Samantaray, A | 1 |
| Chandra, A | 1 |
| Panigrahi, S | 1 |
| Ayoub, CM | 2 |
| Sfeir, PM | 2 |
| Bou-Khalil, P | 1 |
| Azar, M | 1 |
| Haddadin, AS | 1 |
| Harfouch, D | 1 |
| Nasr, VG | 1 |
| El-Khatib, MF | 2 |
| Mishkin, JD | 1 |
| Saxonhouse, SJ | 1 |
| Woo, GW | 1 |
| Burkart, TA | 1 |
| Miles, WM | 4 |
| Conti, JB | 1 |
| Schofield, RS | 1 |
| Sears, SF | 1 |
| Aranda, JM | 1 |
| Rudolph, T | 1 |
| Knudsen, K | 1 |
| Eppert, HD | 1 |
| Goddard, KB | 1 |
| Amino, M | 1 |
| Yoshioka, K | 1 |
| Opthof, T | 1 |
| Morita, S | 2 |
| Uemura, S | 1 |
| Tamura, K | 1 |
| Fukushima, T | 1 |
| Higami, S | 1 |
| Otsuka, H | 1 |
| Akieda, K | 1 |
| Shima, M | 1 |
| Fujibayashi, D | 1 |
| Hashida, T | 1 |
| Inokuchi, S | 1 |
| Kodama, I | 3 |
| Tanabe, T | 1 |
| Ji, XF | 1 |
| Li, CS | 1 |
| Wang, S | 1 |
| Yang, L | 1 |
| Cong, LH | 1 |
| Morita, Y | 1 |
| Mizuno, J | 1 |
| Yoshimura, T | 1 |
| Busch, MC | 1 |
| Haap, M | 1 |
| Kristen, A | 1 |
| Haas, CS | 1 |
| Van Herendael, H | 1 |
| Piccini, JP | 1 |
| Schulte, PJ | 1 |
| Pieper, KS | 1 |
| Mehta, RH | 1 |
| White, HD | 1 |
| Van de Werf, F | 1 |
| Ardissino, D | 1 |
| Califf, RM | 1 |
| Granger, CB | 1 |
| Ohman, EM | 1 |
| Alexander, JH | 1 |
| Suzuki, S | 1 |
| Iwasaki, T | 1 |
| Morimatsu, H | 1 |
| Yokoi, N | 1 |
| Matsuoka, M | 1 |
| Suemori, T | 1 |
| Kanazawa, T | 1 |
| Shimizu, K | 1 |
| Toda, Y | 1 |
| Morita, K | 1 |
| Sohns, C | 1 |
| Zabel, M | 1 |
| Dizon, J | 1 |
| Dizon, S | 1 |
| Biviano, A | 1 |
| Whang, W | 1 |
| Ehlert, F | 1 |
| Vazquez, J | 1 |
| Nazif, T | 1 |
| Garan, H | 3 |
| Auer, J | 1 |
| Lamm, G | 1 |
| Osaka, T | 1 |
| Yokoyama, E | 1 |
| Hasebe, H | 1 |
| Lang, ES | 1 |
| Browning, K | 1 |
| Pang, Y | 1 |
| Ren, S | 1 |
| Zhou, J | 1 |
| Ling, T | 1 |
| Gu, G | 1 |
| Huang, J | 2 |
| Huang, C | 1 |
| Derejko, M | 1 |
| Derejko, P | 1 |
| Przybylski, A | 1 |
| Niewiadomska, M | 1 |
| Antczak, J | 1 |
| Banach, M | 1 |
| Rakowicz, M | 1 |
| Szumowski, Ł | 1 |
| Walczak, F | 3 |
| Goegelein, H | 1 |
| Gautier, P | 1 |
| Roccon, A | 1 |
| O'Connor, S | 1 |
| Ruetten, H | 2 |
| Jurado Román, A | 1 |
| Rubio Alonso, B | 1 |
| Martín Asenjo, R | 1 |
| Salguero Bodes, R | 1 |
| López Gil, M | 1 |
| Arribas Ynsaurriaga, F | 1 |
| Wayne, M | 1 |
| McDonnell, M | 1 |
| Kowey, PR | 9 |
| Crijns, HJ | 2 |
| Aliot, EM | 1 |
| Capucci, A | 4 |
| Kulakowski, P | 1 |
| Radzik, D | 1 |
| Roy, D | 3 |
| Connolly, SJ | 8 |
| Hohnloser, SH | 4 |
| Zhou, SX | 2 |
| Fang, C | 1 |
| Zheng, SX | 1 |
| Zhang, YL | 1 |
| Lei, J | 1 |
| Wang, JF | 1 |
| Billman, GE | 1 |
| Gögelein, H | 1 |
| Wirth, KJ | 1 |
| Marinelli, A | 1 |
| Chevalier, P | 2 |
| Timour, Q | 1 |
| Morel, E | 1 |
| Bui-Xuan, B | 1 |
| Jamshidi, Y | 1 |
| Nolte, IM | 1 |
| Dalageorgou, C | 1 |
| Zheng, D | 1 |
| Johnson, T | 1 |
| Bastiaenen, R | 1 |
| Ruddy, S | 1 |
| Talbott, D | 1 |
| Norris, KJ | 1 |
| Snieder, H | 1 |
| George, AL | 1 |
| Marshall, V | 1 |
| Shakir, S | 1 |
| Kannankeril, PJ | 1 |
| Munroe, PB | 1 |
| Camm, AJ | 2 |
| Jeffery, S | 1 |
| Roden, DM | 1 |
| Behr, ER | 1 |
| Mauermann, WJ | 1 |
| Pulido, JN | 1 |
| Barbara, DW | 1 |
| Abel, MD | 1 |
| Li, Z | 1 |
| Meade, LA | 1 |
| Schaff, HV | 1 |
| White, RD | 1 |
| Boyce, BA | 1 |
| Yee, BH | 1 |
| Vischer, AS | 1 |
| Sticherling, C | 1 |
| Kühne, MS | 1 |
| Osswald, S | 1 |
| Schaer, BA | 1 |
| Ozturk, MA | 1 |
| Ozveren, O | 1 |
| Cinar, V | 1 |
| Erdik, B | 1 |
| Oyan, B | 1 |
| Yonezawa, M | 1 |
| Komuro, I | 1 |
| Ohnishi, S | 3 |
| Silfvast, T | 1 |
| Pettilä, V | 1 |
| Spivack, C | 1 |
| Ballew, KA | 2 |
| Philbrick, JT | 2 |
| Tomkiewicz, W | 1 |
| Meininghaus, DG | 1 |
| Langes, K | 1 |
| Spehn, J | 1 |
| Singh, BN | 9 |
| Hsu, J | 1 |
| Uratsu, C | 1 |
| Truman, A | 1 |
| Quesenberry, C | 1 |
| McDonald, KM | 2 |
| Hlatky, MA | 2 |
| Selby, J | 1 |
| Owens, DK | 1 |
| Sanders, GD | 1 |
| Heidenreich, PA | 1 |
| Seniuk, W | 1 |
| Mularek-Kubzdela, T | 1 |
| Grygier, M | 1 |
| Grajek, S | 1 |
| Cieśliński, A | 1 |
| Renfroe, EG | 1 |
| Heywood, G | 1 |
| Foreman, L | 1 |
| Schron, E | 3 |
| Baessler, C | 2 |
| Warwick, D | 1 |
| Morris, M | 1 |
| Hallstrom, A | 2 |
| Szili-Torok, T | 1 |
| Theuns, D | 1 |
| Verblaauw, T | 1 |
| Scholten, M | 1 |
| Kimman, GJ | 1 |
| Res, J | 1 |
| Jordaens, L | 1 |
| Willan, AR | 1 |
| Chen, EB | 1 |
| Cook, RJ | 1 |
| Lin, DY | 1 |
| Taylor, SE | 1 |
| Emori, T | 1 |
| Ohta, K | 1 |
| Morita, H | 1 |
| Matsubara, H | 1 |
| Sano, S | 1 |
| Ohe, T | 2 |
| Stoner, J | 1 |
| Martin, G | 1 |
| O'Mara, K | 1 |
| Ehlers, J | 1 |
| Tomlanovich, M | 1 |
| Kirchhof, P | 1 |
| Degen, H | 1 |
| Franz, MR | 2 |
| Fabritz, L | 1 |
| Läer, S | 1 |
| Neumann, J | 1 |
| Haverkamp, W | 4 |
| Crystal, E | 1 |
| Kahn, S | 1 |
| Roberts, R | 3 |
| Thorpe, K | 2 |
| Gent, M | 5 |
| Cairns, JA | 2 |
| Moulik, PK | 1 |
| Attar, MN | 1 |
| Rose, EL | 1 |
| Khaleeli, AA | 1 |
| Sarkozy, A | 1 |
| Xavier, LC | 1 |
| Kern, KB | 2 |
| Steinbigler, P | 1 |
| Haberl, R | 1 |
| Franks, AM | 1 |
| Watterson, KS | 1 |
| Paiva, EF | 1 |
| Perondi, MB | 1 |
| Timerman, S | 1 |
| Cardoso, LF | 1 |
| Ramirez, JA | 1 |
| Ohkubo, K | 1 |
| Watanabe, I | 1 |
| Okumura, Y | 1 |
| Yamada, T | 1 |
| Masaki, R | 1 |
| Kofune, T | 1 |
| Oshikawa, N | 1 |
| Kasamaki, Y | 1 |
| Saito, S | 1 |
| Ozawa, Y | 1 |
| Kanmatsuse, K | 1 |
| Srivatsa, UN | 1 |
| Ebrahimi, R | 1 |
| El-Bialy, A | 1 |
| Wachsner, RY | 1 |
| Sharma, AD | 1 |
| Fain, E | 2 |
| O'Neill, PG | 1 |
| Skadsen, A | 1 |
| Damle, R | 1 |
| Baker, J | 1 |
| Chauhan, V | 1 |
| Mazuz, M | 1 |
| Ross, T | 1 |
| Zhang, Z | 1 |
| Kulasingam, SL | 1 |
| Akiyama, T | 2 |
| Mounsey, JP | 1 |
| Ledingham, R | 2 |
| Hallstrom, AP | 4 |
| Tsagalou, EP | 1 |
| Anastasiou-Nana, MI | 2 |
| Charitos, CE | 1 |
| Siafakas, CX | 1 |
| Drakos, SG | 1 |
| Ntalianis, A | 1 |
| Terrovitis, JV | 1 |
| Mavrikakis, EM | 1 |
| Doufas, A | 1 |
| Nanas, JN | 2 |
| Díaz-Castro, O | 1 |
| Puchol, A | 1 |
| Almendral, J | 1 |
| Torrecilla, EG | 1 |
| Arenal, A | 1 |
| Martínez-Selles, M | 1 |
| Bokhari, F | 1 |
| Newman, D | 2 |
| Greene, M | 1 |
| Korley, V | 1 |
| Mangat, I | 1 |
| Wellens, HJ | 2 |
| Aiba, T | 1 |
| Shimizu, W | 2 |
| Inagaki, M | 1 |
| Satomi, K | 2 |
| Taguchi, A | 1 |
| Kurita, T | 3 |
| Suyama, K | 2 |
| Aihara, N | 2 |
| Sunagawa, K | 1 |
| Kamakura, S | 2 |
| Pueyo, E | 1 |
| Smetana, P | 1 |
| Caminal, P | 1 |
| de Luna, AB | 1 |
| Malik, M | 1 |
| Laguna, P | 1 |
| Lakhotia, R | 1 |
| Basvaraj, S | 1 |
| Kumar, M | 1 |
| Dubey, B | 1 |
| Mohanty, S | 1 |
| Kumar, R | 1 |
| Hong, MF | 1 |
| Rätz Bravo, AE | 1 |
| Drewe, J | 1 |
| Schlienger, RG | 1 |
| Krähenbühl, S | 1 |
| Pargger, H | 1 |
| Ummenhofer, W | 1 |
| Nagasawa, Y | 1 |
| Chen, J | 1 |
| Hashimoto, K | 1 |
| Mikroulis, D | 1 |
| Didilis, V | 1 |
| Konstantinou, F | 1 |
| Tsakiridis, K | 1 |
| Vretzakis, G | 1 |
| Bougioukas, G | 1 |
| Yan, GX | 2 |
| Shukla, G | 1 |
| Chaudhry, GM | 1 |
| Orlov, M | 1 |
| Hoffmeister, P | 1 |
| Haffajee, C | 1 |
| Roberts, RS | 2 |
| Bailin, S | 1 |
| Fain, ES | 1 |
| Champagne, J | 2 |
| Coutu, B | 1 |
| Gronefeld, GC | 1 |
| Letsas, KP | 1 |
| Filippatos, GS | 1 |
| Kounas, SP | 1 |
| Efremidis, M | 1 |
| Sideris, A | 1 |
| Kardaras, F | 1 |
| Somberg, J | 1 |
| Molnar, J | 1 |
| Yuge, M | 1 |
| Niwano, S | 1 |
| Moriguchi, M | 1 |
| Sasaki, T | 1 |
| Hirasawa, S | 1 |
| Imaki, R | 1 |
| Sato, D | 1 |
| Izumi, T | 1 |
| Mitamura, H | 1 |
| Aizawa, Y | 2 |
| Nitta, T | 1 |
| Aonuma, K | 1 |
| Tsuboi, N | 1 |
| Chinushi, M | 1 |
| Kobayashi, Y | 1 |
| Soejima, K | 1 |
| Furushima, H | 1 |
| Ogawa, S | 1 |
| Ohtsu, H | 1 |
| Yamazaki, T | 1 |
| Uzan, L | 1 |
| Guignat, L | 1 |
| Meune, C | 1 |
| Mouly, S | 1 |
| Weber, S | 1 |
| Bertagna, X | 1 |
| Bertherat, J | 1 |
| Thomopoulos, P | 1 |
| Duboc, D | 1 |
| Sugi, K | 1 |
| Iavelov, IS | 1 |
| Lu, LX | 1 |
| Zhou, W | 1 |
| Zhang, X | 2 |
| Cao, Q | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Stockman, W | 1 |
| De Keyser, J | 1 |
| Brabant, S | 1 |
| Spoelders, K | 1 |
| Vuylsteke, P | 1 |
| Beeuwsaert, R | 1 |
| Coppé, E | 1 |
| Kukla, P | 1 |
| Bryniarski, L | 1 |
| Dragan, J | 1 |
| Słowiak-Lewińska, T | 1 |
| Czamara, M | 1 |
| Bromblik, A | 1 |
| Szczuka, K | 1 |
| Karaoguz, R | 2 |
| Maydanozcu, S | 1 |
| Altun, T | 1 |
| Güldal, M | 2 |
| Akyürek, O | 1 |
| Erol, C | 1 |
| Pollet, P | 1 |
| Goethals, M | 1 |
| Wang, K | 2 |
| Deng, X | 1 |
| Xu, Z | 1 |
| Li, S | 1 |
| Liu, Y | 1 |
| Guo, R | 1 |
| Patwardhan, A | 2 |
| Leonelli, F | 2 |
| Agelaki, MG | 1 |
| Pantos, C | 1 |
| Korantzopoulos, P | 1 |
| Tsalikakis, DG | 1 |
| Baltogiannis, GG | 1 |
| Fotopoulos, A | 1 |
| Kolettis, TM | 1 |
| Mironchik, EV | 1 |
| Dolgosheĭ, TS | 1 |
| Liskovich, TG | 1 |
| Madeshkina, GA | 1 |
| Kokhkovski, AB | 1 |
| Tyshchenko, AD | 1 |
| Tempe, DK | 1 |
| Gandhi, A | 1 |
| Mehta, V | 1 |
| Banerjee, A | 1 |
| Datt, V | 1 |
| Ramamurthy, P | 1 |
| Goyal, G | 1 |
| Joshi, S | 1 |
| Raiszadeh, F | 1 |
| Pierce, W | 1 |
| Steinberg, JS | 2 |
| Dennison, P | 1 |
| Zaremba, E | 1 |
| Parsai, C | 1 |
| Bonvini, RF | 1 |
| Schnetzler, B | 1 |
| Sunthorn, H | 1 |
| Fideler, FJ | 1 |
| Dieterich, HJ | 1 |
| Schroeder, TH | 1 |
| Lima, CE | 1 |
| Martinelli Filho, M | 1 |
| Silva, RT | 1 |
| Tamaki, WT | 1 |
| Oliveira, JC | 1 |
| Martins, DC | 1 |
| Nishióka, SA | 1 |
| Pedrosa, AA | 1 |
| Siqueira, SF | 1 |
| Costa, R | 1 |
| Lüderitz, B | 3 |
| Manz, M | 3 |
| Steinbeck, G | 2 |
| Pelleg, A | 1 |
| Miller, HI | 1 |
| Laniado, S | 1 |
| Morady, F | 6 |
| Hess, DS | 1 |
| Waxman, HL | 4 |
| Groh, WC | 1 |
| Buxton, AE | 3 |
| Sadowski, LM | 1 |
| Horowitz, LN | 6 |
| Josephson, ME | 3 |
| Kastor, JA | 1 |
| Marcus, FI | 2 |
| Maheswaran, R | 1 |
| Bramble, MG | 1 |
| Hardisty, CA | 1 |
| Saksena, S | 2 |
| Rothbart, ST | 1 |
| Shah, Y | 1 |
| Cappello, G | 1 |
| Rotmensch, HH | 1 |
| Swanson, BN | 1 |
| Shoshani, D | 1 |
| Spielman, SR | 5 |
| Greenspon, AJ | 1 |
| Greenspan, AM | 4 |
| Vlasses, PH | 1 |
| Anastasiou-Nana, M | 1 |
| Koutras, DA | 1 |
| Levis, G | 1 |
| Souvatzoglou, A | 1 |
| Boukis, MA | 1 |
| Moulopoulos, SD | 2 |
| Raviele, A | 2 |
| Di Pede, F | 2 |
| Delise, P | 2 |
| Piccolo, E | 2 |
| Weber, H | 1 |
| Weissel, M | 2 |
| Haddad, R | 1 |
| Scheibelhofer, W | 1 |
| Konrad, K | 1 |
| Mlczoch, J | 1 |
| Probst, P | 1 |
| Mainitz, M | 1 |
| Heger, JJ | 6 |
| Solow, EB | 1 |
| Prystowsky, EN | 6 |
| Zipes, DP | 6 |
| Johns, JA | 1 |
| Harper, RW | 1 |
| Currie, PJ | 1 |
| Federman, J | 1 |
| Anderson, ST | 1 |
| Pitt, A | 1 |
| Ruskin, JN | 3 |
| DiMarco, JP | 3 |
| Derkac, WM | 1 |
| Akins, CW | 1 |
| Daggett, WM | 1 |
| Austen, WG | 1 |
| Buckley, MJ | 1 |
| Webb, CR | 2 |
| Kay, HR | 4 |
| Nademanee, K | 3 |
| Weiss, J | 1 |
| Feld, G | 1 |
| Stevenson, WG | 2 |
| Patterson, E | 1 |
| Eller, BT | 1 |
| Abrams, GD | 1 |
| Vasiliades, J | 1 |
| Lucchesi, BR | 1 |
| Shen, E | 1 |
| Schwartz, A | 1 |
| Hess, D | 1 |
| Bhandari, A | 2 |
| Sung, RJ | 2 |
| Sauve, MJ | 4 |
| Malone, P | 3 |
| Shen, EN | 1 |
| Schwartz, AB | 1 |
| Keung, E | 1 |
| McGovern, B | 2 |
| Malacoff, RF | 1 |
| Grant, G | 1 |
| Sellers, TD | 2 |
| Reddy, CP | 1 |
| Kuo, CS | 1 |
| Mostow, ND | 3 |
| Rakita, L | 2 |
| Vrobel, TR | 2 |
| Noon, D | 1 |
| Blumer, J | 1 |
| Spadaro, J | 1 |
| Hashimoto, LM | 1 |
| Franco, RS | 1 |
| Bregagnollo, EA | 1 |
| Tucci, PJ | 1 |
| Chapman, JR | 1 |
| Boyd, MJ | 2 |
| Jackman, WM | 1 |
| Naccarelli, GV | 3 |
| Warfel, KA | 1 |
| Rinkenberger, RL | 1 |
| Fogoros, RN | 1 |
| Anderson, KP | 1 |
| Winkle, RA | 3 |
| Swerdlow, CD | 2 |
| Mason, JW | 2 |
| Labrid, C | 1 |
| Leinot, M | 1 |
| Beaughard, M | 1 |
| Basiez, M | 1 |
| Duchene-Marullaz, P | 1 |
| Griffin, JC | 3 |
| Ross, DL | 1 |
| Keefe, DL | 1 |
| Clusin, WT | 1 |
| Stoliarchuk, AA | 1 |
| Storozhuk, BG | 1 |
| McComb, JM | 1 |
| Logan, KR | 1 |
| Khan, MM | 1 |
| Geddes, JS | 1 |
| Adgey, AA | 1 |
| Naito, M | 1 |
| Michelson, EL | 1 |
| Kmetzo, JJ | 1 |
| Kaplinsky, E | 1 |
| Dreifus, LS | 1 |
| Singer, I | 1 |
| Schmitt, C | 2 |
| Montero, M | 1 |
| Melichercik, J | 1 |
| Kojima, S | 1 |
| Wu, ST | 1 |
| Wikman-Coffelt, J | 1 |
| Parmley, WW | 1 |
| Jalal, S | 1 |
| Levine, JH | 4 |
| Herre, JM | 4 |
| Pacifico, A | 1 |
| Lindsay, BD | 1 |
| Plumb, VJ | 1 |
| Janosik, DL | 1 |
| Kopelman, HA | 2 |
| Friehling, T | 1 |
| Chilson, DA | 2 |
| Platia, EV | 2 |
| Szabó, BM | 1 |
| Wiesfeld, AC | 1 |
| van Veldhuisen, DJ | 1 |
| Hillege, HL | 1 |
| Lie, KI | 1 |
| Garguichevich, JJ | 1 |
| Ramos, JL | 1 |
| Gambarte, A | 1 |
| Gentile, A | 1 |
| Hauad, S | 1 |
| Scapin, O | 1 |
| Sirena, J | 1 |
| Tibaldi, M | 1 |
| Toplikar, J | 1 |
| Jung, W | 2 |
| Pfeiffer, D | 2 |
| Tebbenjohanns, J | 1 |
| Pizzulli, L | 2 |
| Siebels, J | 3 |
| Cappato, R | 2 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 3 |
| Weiss, JN | 2 |
| Kasanuki, H | 3 |
| Inaba, T | 1 |
| Ohnisi, S | 1 |
| Shoda, M | 1 |
| Matuda, N | 1 |
| Hosoda, S | 2 |
| Kopp, DE | 1 |
| Blakeman, BP | 1 |
| Kall, JG | 1 |
| Olshansky, B | 2 |
| Kinder, CA | 1 |
| Johnson, G | 1 |
| Dolack, GL | 2 |
| Greene, HL | 5 |
| Wyse, DG | 2 |
| Zipes, D | 1 |
| Epstein, AE | 4 |
| Domanski, MJ | 2 |
| Schron, EB | 1 |
| Lévy, S | 1 |
| Liu, PM | 1 |
| Zhang, XM | 2 |
| Wu, W | 3 |
| Li, JM | 1 |
| Tang, Y | 1 |
| Candinas, R | 1 |
| Bauersfeld, U | 1 |
| Wilson, FS | 1 |
| Ovadia, M | 1 |
| Brito, M | 1 |
| Hoyer, GL | 1 |
| Proclemer, A | 2 |
| Facchin, D | 2 |
| Feruglio, GA | 2 |
| Nucifora, R | 1 |
| Bellone, P | 1 |
| Spirito, P | 1 |
| Vecchio, C | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Van de Loo, A | 1 |
| Hohnloser, S | 1 |
| Just, H | 1 |
| Ahmed, R | 1 |
| Buja, G | 1 |
| Miorelli, M | 1 |
| Turrini, P | 1 |
| Melacini, P | 1 |
| Nava, A | 1 |
| Vanuzzo, D | 1 |
| Maynard, C | 1 |
| Russo, AM | 1 |
| Beauregard, LM | 1 |
| Nanas, SN | 1 |
| Rapti, A | 1 |
| Poyadjis, A | 1 |
| Stathaki, S | 1 |
| Akalin, H | 1 |
| Bayar, M | 1 |
| Akyol, T | 1 |
| McCollam, PL | 1 |
| Nappi, JM | 1 |
| Sager, PT | 1 |
| Uppal, P | 1 |
| Follmer, C | 1 |
| Antimisiaris, M | 1 |
| Pruitt, C | 1 |
| Tisi, G | 1 |
| Baroffio, R | 1 |
| Croce, A | 1 |
| Olson, PJ | 1 |
| Woelfel, A | 2 |
| Simpson, RJ | 2 |
| Foster, JR | 2 |
| Gøtzsche, LS | 1 |
| Pedersen, EM | 1 |
| Paulsen, PK | 1 |
| Lapinsky, SE | 1 |
| Mullen, JB | 1 |
| Balter, MS | 1 |
| Massumi, A | 1 |
| Gomes, A | 1 |
| Woosley, RL | 1 |
| Anderson, JL | 3 |
| Brooks, MM | 1 |
| Peckova, M | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 2 |
| Manning, AS | 1 |
| Bruyninckx, C | 1 |
| Ramboux, J | 1 |
| Rodríguez, LM | 1 |
| Sternick, EB | 1 |
| Smeets, JL | 1 |
| Timmermans, C | 1 |
| den Dulk, K | 1 |
| Oreto, G | 1 |
| Boriani, G | 2 |
| Biffi, M | 1 |
| Frabetti, L | 1 |
| Azzolini, U | 1 |
| Sabbatani, P | 1 |
| Bronzetti, G | 1 |
| Magnani, B | 2 |
| Pethig, K | 1 |
| Wahlers, T | 1 |
| Tager, S | 1 |
| Borst, HG | 1 |
| Wood, MK | 1 |
| Martens, P | 1 |
| Vandekerckhove, Y | 1 |
| Fleurant, E | 1 |
| Lacroix, D | 1 |
| Klug, D | 1 |
| Warembourg, H | 1 |
| Kacet, S | 1 |
| Lekieffre, J | 1 |
| Lazzara, R | 1 |
| Liu, P | 1 |
| Fei, L | 1 |
| Li, J | 1 |
| Wang, J | 1 |
| Korth-Bradley, JM | 1 |
| Rose, GM | 1 |
| de Vane, PJ | 1 |
| Peters, J | 1 |
| Chiang, ST | 1 |
| Chorro, FJ | 1 |
| Sánchez-Muñoz, JJ | 1 |
| Sanchis, J | 1 |
| Cortina, J | 1 |
| Bataller, M | 1 |
| Guerrero, J | 1 |
| Espí, J | 1 |
| Ruipérez, JA | 1 |
| López-Merino, V | 1 |
| Bourret, N | 1 |
| Kirkorian, G | 1 |
| Bellon, C | 1 |
| Richalet, C | 1 |
| Bouchayer, D | 1 |
| Bonnefoy, E | 1 |
| Touboul, P | 2 |
| Takeichi, K | 1 |
| Endoh, Y | 1 |
| Grimm, W | 1 |
| Steder, U | 1 |
| Menz, V | 1 |
| Hoffmann, J | 1 |
| Maisch, B | 1 |
| Borggrefe, M | 4 |
| Block, M | 1 |
| Böcker, D | 2 |
| Manolis, AG | 2 |
| Katsivas, A | 1 |
| Lazaris, E | 1 |
| Koutsogeogis, D | 1 |
| Louvros, N | 1 |
| Muratore, C | 1 |
| Rabinovich, R | 1 |
| Iglesias, R | 1 |
| González, M | 1 |
| Darú, V | 1 |
| Liprandi, AS | 1 |
| Marinchak, RA | 4 |
| Rials, SJ | 2 |
| Filart, RA | 1 |
| Neuzner, J | 1 |
| Bahawar, H | 1 |
| Berkowitsch, A | 1 |
| Michel, U | 1 |
| Schlepper, M | 1 |
| Pitschner, HF | 1 |
| Behrens, S | 1 |
| Li, C | 1 |
| Veerakul, G | 1 |
| Nimmannit, S | 1 |
| Chaowakul, V | 1 |
| Bhuripanyo, K | 1 |
| Likittanasombat, K | 1 |
| Tunsanga, K | 1 |
| Kuasirikul, S | 1 |
| Malasit, P | 1 |
| Tansupasawadikul, S | 1 |
| Tatsanavivat, P | 1 |
| Myerburg, RJ | 2 |
| Castellanos, A | 2 |
| Pedersen, HK | 1 |
| Jacobsen, EA | 1 |
| Mortensen, E | 1 |
| Refsum, H | 1 |
| Matsuo, K | 1 |
| Shimomura, K | 1 |
| Halawa, B | 1 |
| Brugada, J | 1 |
| Brugada, R | 1 |
| Brugada, P | 1 |
| Votey, SR | 1 |
| Herbert, ME | 1 |
| Bessho, R | 1 |
| Tresch, DD | 1 |
| Thakur, RK | 1 |
| Petrovic, T | 1 |
| Adnet, F | 1 |
| Lapandry, C | 1 |
| Klein, H | 2 |
| Auricchio, A | 1 |
| Reek, S | 1 |
| Geller, C | 1 |
| Villain, E | 1 |
| Bonnet, D | 1 |
| Acar, P | 1 |
| Aggoun, Y | 1 |
| Sidi, D | 1 |
| Kachaner, J | 1 |
| Elliott, PM | 1 |
| Sharma, S | 1 |
| Varnava, A | 1 |
| Poloniecki, J | 1 |
| Rowland, E | 1 |
| McKenna, WJ | 1 |
| Chen, XC | 1 |
| Tomcsányi, J | 1 |
| Merkely, B | 1 |
| Tenczer, J | 1 |
| Papp, L | 1 |
| Karlócai, K | 1 |
| Chen, BP | 2 |
| White, CM | 2 |
| Fan, C | 2 |
| Kluger, J | 2 |
| Chow, MS | 2 |
| Exner, DV | 1 |
| Reiter, MJ | 1 |
| Yao, Q | 2 |
| Duff, HJ | 2 |
| Follmann, D | 1 |
| Carlson, MD | 1 |
| Brodsky, MA | 2 |
| Zhou, L | 1 |
| Cobb, LA | 1 |
| Copass, MK | 1 |
| Cummins, RO | 1 |
| Doherty, AM | 1 |
| Fahrenbruch, CE | 1 |
| Murray, WA | 1 |
| Olsufka, M | 1 |
| Walsh, T | 1 |
| Groh, WJ | 1 |
| Shinn, TS | 1 |
| Engelstein, EE | 1 |
| Sakseena, S | 1 |
| Kim, S | 1 |
| Lancaster, S | 2 |
| Ocampo, C | 1 |
| Rosenberg, Y | 1 |
| Naccarella, F | 1 |
| Rolli, A | 1 |
| Carboni, A | 1 |
| Finardi, A | 1 |
| Aurier, E | 1 |
| Favaro, L | 1 |
| Contini, S | 1 |
| Gherli, T | 1 |
| Caponi, D | 1 |
| Maranga, SS | 1 |
| Lepera, G | 1 |
| Bartoletti, A | 1 |
| Bharucha, DB | 1 |
| Zivin, A | 1 |
| Zado, ES | 1 |
| Deely, MP | 1 |
| Saligan, J | 1 |
| Ashar, M | 1 |
| Nayak, H | 1 |
| Ogunyankin, KO | 1 |
| Yap, YG | 1 |
| Dorwarth, U | 1 |
| Hoffmann, E | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Kalla, H | 1 |
| Marinchak, R | 1 |
| Sheldon, RS | 1 |
| Green, MS | 1 |
| Klein, GJ | 1 |
| O'Brien, B | 1 |
| Berkman, M | 1 |
| Leclercq, JF | 2 |
| Edwards, KE | 1 |
| Wenstone, R | 1 |
| Moghe, S | 1 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Frankenberger, O | 1 |
| Della Bella, P | 1 |
| Konecná, P | 1 |
| Dvorák, R | 1 |
| Semrád, B | 1 |
| Erich, J | 1 |
| Okishige, K | 1 |
| Sasano, T | 1 |
| Yano, K | 1 |
| Azegami, K | 1 |
| Suzuki, K | 1 |
| Itoh, K | 1 |
| Stewart, CE | 1 |
| Taneda, K | 1 |
| Omichi, C | 1 |
| Zhou, S | 1 |
| Lee, MH | 1 |
| Naik, A | 1 |
| Chang, CM | 1 |
| Garfinkel, A | 1 |
| Karagueuzian, HS | 1 |
| Katsivas, AG | 1 |
| Vassilopoulos, C | 1 |
| Tsatiris, CG | 1 |
| Cass, D | 1 |
| Schwartz, B | 1 |
| Cooper, R | 1 |
| Gelaznikas, R | 1 |
| Barr, A | 1 |
| Siegers, A | 1 |
| Board, PN | 1 |
| Alboni, P | 1 |
| Skinner, JL | 1 |
| Rogers, JM | 1 |
| Smith, WM | 1 |
| Holman, WL | 1 |
| Ideker, RE | 1 |
| Van Schepdael, J | 1 |
| Solvay, H | 1 |
| Brochier, M | 1 |
| Fauchier, JP | 1 |
| Lubbe, WF | 1 |
| McFadyen, ML | 1 |
| Muller, CA | 1 |
| Worthington, M | 1 |
| Opie, LH | 1 |
| Koch-Weser, J | 1 |
| Derrida, JP | 1 |
| Ollagnier, J | 1 |
| Benaim, R | 1 |
| Haiat, R | 1 |
| Chiche, P | 1 |
| Veglia, L | 1 |
| Scandiffio, T | 1 |
| Guerricchio, G | 1 |
| Rosenbaum, MB | 1 |
| Chiale, PA | 1 |
| Halpern, MS | 1 |
| Nau, GJ | 1 |
| Przybylski, J | 1 |
| Levi, RJ | 1 |
| Lázzari, JO | 1 |
| Elizari, MV | 1 |
| Shenasa, M | 1 |
| Hindricks, G | 1 |
| Huikuri, HV | 1 |
| Yli-Mäyry, S | 1 |
| von Planta, M | 1 |
| Chamberlain, D | 1 |
| O'Brien, BJ | 1 |
| Buxton, MJ | 1 |
| Rushby, JA | 1 |
| Leenhardt, A | 1 |
| Coumel, P | 1 |
| Slama, R | 1 |
| Zhang, JF | 1 |
| Liu, J | 1 |
| Liu, XZ | 1 |
| Kato, K | 1 |
| Summitt, J | 1 |
| Kadish, A | 1 |
| Khastgir, T | 1 |
| Lattuca, J | 1 |
| Aarons, D | 1 |
| Murphy, J | 1 |
| O'Mara, V | 1 |
| Juanteguy, J | 2 |
| Veltri, EP | 2 |
| Burckhardt, D | 1 |
| Robertson, A | 1 |
| Hoffmann, A | 1 |
| Pfisterer, M | 1 |
| Huang, SK | 1 |
| Tan de Guzman, WL | 1 |
| Chenarides, JG | 1 |
| Okike, NO | 1 |
| Vander Salm, TJ | 1 |
| Gasparini, G | 1 |
| Zanocco, A | 1 |
| Bonso, A | 1 |
| D'Este, D | 1 |
| Abdollah, H | 1 |
| Brennan, FJ | 1 |
| Jimmo, S | 1 |
| Brien, JF | 1 |
| Gilligan, DM | 1 |
| Missouris, CG | 1 |
| Oakley, CM | 1 |
| Nalos, PC | 2 |
| Ismail, Y | 1 |
| Pappas, JM | 1 |
| Nyitray, W | 1 |
| DonMichael, TA | 1 |
| Rosalion, A | 1 |
| Snow, NJ | 1 |
| Horrigan, TP | 1 |
| Noon, DL | 1 |
| Quieffin, J | 1 |
| Brochet, E | 1 |
| Gamerman, G | 1 |
| Assayag, P | 1 |
| Antony, I | 1 |
| Valère, PE | 1 |
| Lambert, C | 1 |
| Mossiat, C | 1 |
| Tannière-Zeller, M | 1 |
| Maupoil, V | 1 |
| Rochette, L | 1 |
| Goedel-Meinen, L | 1 |
| Hofmann, M | 1 |
| Schmidt, G | 1 |
| Maier-Rudolph, W | 1 |
| Barthel, P | 1 |
| Schrag, A | 1 |
| Baedeker, W | 1 |
| Blömer, H | 1 |
| Myers, M | 1 |
| Peter, T | 1 |
| Weiss, D | 1 |
| Gang, ES | 1 |
| Oseran, DS | 1 |
| Mandel, WJ | 1 |
| Strasberg, B | 2 |
| Kusniec, J | 2 |
| Zlotikamien, B | 1 |
| Mager, A | 1 |
| Sclarovsky, S | 2 |
| Gilbert, J | 1 |
| Gold, RL | 2 |
| Haffajee, CI | 2 |
| Alpert, JS | 2 |
| Frame, LH | 1 |
| O'Connor, KM | 1 |
| Friehling, TD | 2 |
| Reĭngardene, DI | 1 |
| Schützenberger, W | 1 |
| Leisch, F | 1 |
| Kerschner, K | 1 |
| Harringer, W | 1 |
| Herbinger, W | 1 |
| Mercereau, D | 1 |
| Kubac, G | 1 |
| Klinke, WP | 1 |
| Williams, ML | 1 |
| Cascio, WE | 1 |
| Gettes, LS | 1 |
| Gillis, AM | 1 |
| Mattioni, TA | 1 |
| Zheutlin, TA | 1 |
| Sarmiento, JJ | 1 |
| Parker, M | 1 |
| Lesch, M | 1 |
| Kehoe, RF | 1 |
| Ochi, RP | 1 |
| Goldenberg, IF | 1 |
| Almquist, A | 1 |
| Pritzker, M | 1 |
| Milstein, S | 1 |
| Pedersen, W | 1 |
| Gobel, FL | 1 |
| Benditt, DG | 1 |
| Helmy, I | 1 |
| Langberg, JJ | 1 |
| Goldberg, H | 1 |
| Gueugniaud, PY | 1 |
| Guérin, C | 1 |
| Mahul, P | 1 |
| Robert, D | 1 |
| Bertin-Maghit, M | 1 |
| Buisson, A | 1 |
| Wyndham, CR | 1 |
| Podrid, PJ | 1 |
| Gonzalez, R | 1 |
| Sharkey, H | 1 |
| De Paola, AA | 1 |
| Brady, P | 1 |
| Morganroth, J | 2 |
| Sulpizi, AM | 1 |
| Stohler, JL | 1 |
| Klein, LS | 1 |
| Fineberg, N | 1 |
| Kammerling, JM | 1 |
| Chang, MS | 1 |
| Caspi, A | 1 |
| Lewin, RF | 1 |
| Agmon, J | 1 |
| Trampisch, HJ | 1 |
| Balducelli, M | 1 |
| Popławska, W | 2 |
| Chlewicka, I | 2 |
| Wójcik, E | 2 |
| Paczkowski, D | 2 |
| Podleśny, J | 2 |
| Rae, AP | 2 |
| Kutalek, SP | 1 |
| Windle, J | 1 |
| Kim, SG | 1 |
| Felder, SD | 1 |
| Figura, I | 1 |
| Johnston, DR | 1 |
| Mercando, AD | 1 |
| Fisher, JD | 1 |
| Brachmann, J | 1 |
| Waldecker, B | 1 |
| Rizos, I | 1 |
| Senges, J | 1 |
| Kübler, W | 1 |
| Yazaki, Y | 1 |
| Bishop, RL | 1 |
| Griffith, LS | 1 |
| Watkins, L | 1 |
| Mower, MM | 1 |
| Mirowski, M | 1 |
| Rosenfeld, LF | 1 |
| Kennedy, EE | 1 |
| Perlmutter, RA | 1 |
| Bookbinder, MJ | 1 |
| McPherson, CA | 1 |
| Batsford, WP | 1 |
| Somberg, JC | 1 |
| Nygaard, TW | 1 |
| Cook, TS | 1 |
| Arredondo, MT | 1 |
| Guillen, SG | 1 |
| Quinteiro, RA | 1 |
| Brown, JH | 1 |
| McLoughlin, JC | 1 |
| Boland, M | 1 |
| DiCarlo, LA | 2 |
| de Buitleir, M | 1 |
| Baerman, JM | 1 |
| Schurig, L | 1 |
| Annesley, T | 1 |
| Lavery, D | 1 |
| Doherty, JU | 2 |
| Kerin, NZ | 1 |
| Blevins, RD | 1 |
| Benaderet, D | 1 |
| Faitel, K | 1 |
| Jarandilla, R | 1 |
| Garfinkel, C | 1 |
| Klein, S | 1 |
| Rubenfire, M | 1 |
| Leak, D | 1 |
| Eydt, JN | 1 |
| Rotmensch, H | 1 |
| Sokoloff, NM | 1 |
| Segal, BL | 1 |
| Davis, JC | 1 |
| Evans-Bell, T | 1 |
| Winston, SA | 1 |
| Flores, BT | 1 |
| Flaker, GC | 1 |
| Alpert, MA | 1 |
| Webel, RR | 1 |
| Ruder, MA | 1 |
| Sanfelippo, JF | 1 |
| Tsutakawa, RK | 1 |
| Hottinger, S | 1 |
| Mettler, D | 1 |
| Leupi, F | 1 |
| Gertsch, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| Etiology, Incidence and Survival of Pediatric Out-of-hospital Cardiac Arrests: a Four-year Danish Analysis[NCT04275856] | 300 participants (Anticipated) | Observational [Patient Registry] | 2019-02-01 | Active, not recruiting | |||
| Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT)[NCT01401647] | Phase 3 | 3,024 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| "Test-No Test Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)"[NCT01905007] | Phase 4 | 100 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death[NCT00993382] | Phase 2 | 486 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| The Use of Amiodarone vs. Lidocaine and Placebo for the Prevention of Ventricular Fibrillation After Myocardial Reperfusion During Cardiopulmonary Bypass[NCT00587483] | 342 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| ECG Device for Long QT Syndrome Screening in Newborns[NCT02412709] | Phase 2 | 4,000 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| [NCT00000531] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504] | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Change in the design of the study) | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140] | 100 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [NCT00000464] | Phase 3 | 0 participants | Interventional | 1987-04-30 | Completed | ||
| Discovering the Genetic Causes of Brugada Syndrome in Thais and Southeast Asian Population[NCT04232787] | 750 participants (Anticipated) | Observational [Patient Registry] | 2016-01-28 | Recruiting | |||
| Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol[NCT01572246] | 167 participants (Actual) | Observational | 2012-05-31 | Completed | |||
| EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy[NCT03259113] | 30 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | |||
| An International, Randomized, Controlled Prehospital Trial of a Waveform-Based Automated External Defibrillation Algorithm for the Management of Ventricular Fibrillation[NCT00535106] | 900 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neurologic status at discharge will be assessed using the modified Rankin Score (MRS). A higher value indicates a worse outcome. 0-No symptoms at all; 1-No significant disability despite symptoms; able to carry out all usual duties and activities, 2-Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, 3-Moderate disability; requiring some help, but able to walk without assistance; 4-Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, 5-Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6-Dead (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | Participants (Count of Participants) |
|---|---|
| Amiodarone | 182 |
| Lidocaine | 172 |
| Normal Saline | 175 |
Patients may die in the field (outside of the hospital at the time of the cardiac arrest), at the emergency room, in the hospital, or they are discharged alive from the hospital. (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | participants (Number) |
|---|---|
| Amiodarone | 237 |
| Lidocaine | 233 |
| Normal Saline | 222 |
(NCT00587483)
Timeframe: Participants were followed from randomization through the 60 minute period following myocardial reperfusion.
| Intervention | Participants (Number) |
|---|---|
| Lidocaine 1.5 mg /kg | 66 |
| Amiodarone 300 mg | 60 |
| Placebo (Saline) | 70 |
(NCT00587483)
Timeframe: Participants were followed from the date of randomization until the date of discharge from the hospital, assessed up to 60 days.
| Intervention | Days (Mean) |
|---|---|
| Lidocaine 1.5 mg /kg | 6.183 |
| Amiodarone 300 mg | 7.5 |
| Placebo (Saline) | 9.423 |
(NCT00587483)
Timeframe: Participants were followed from the date of randomization until the date of discharge from the Intensive Care Unit, assessed up to 40 days.
| Intervention | Days (Mean) |
|---|---|
| Lidocaine 1.5 mg /kg | 1.357 |
| Amiodarone 300 mg | 5.329 |
| Placebo (Saline) | 4.847 |
Number of participants per arm who experienced arrhythmias while on floor care following dismissal from the ICU. (NCT00587483)
Timeframe: Participants were followed from dismissal from the ICU until dismissal from the hospital.
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Ventricular tachycardia | Atrial fibrillation | Other arrhythmias | |
| Amiodarone 300 mg | 2 | 49 | 42 |
| Lidocaine 1.5 mg /kg | 2 | 56 | 36 |
| Placebo (Saline) | 3 | 38 | 24 |
Number of participants per arm who experienced arrhythmias other than ventricular fibrillation while in the ICU. (NCT00587483)
Timeframe: Participants were followed from randomization through the 60 minute period following myocardial reperfusion.
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Ventricular tachycardia | Atrial fibrillation | Other arrhythmias | |
| Amiodarone 300 mg | 2 | 23 | 35 |
| Lidocaine 1.5 mg /kg | 3 | 21 | 27 |
| Placebo (Saline) | 0 | 18 | 27 |
(NCT00587483)
Timeframe: Participants were followed from randomization through the 60 minute period following myocardial reperfusion.
| Intervention | Participants (Number) | ||
|---|---|---|---|
| 0 Attempts | 1 - 3 Attempts | > 3 Attempts | |
| Amiodarone 300 mg | 57 | 43 | 15 |
| Lidocaine 1.5 mg /kg | 46 | 53 | 16 |
| Placebo (Saline) | 40 | 46 | 14 |
Number of participants per arm who required the use of vasopressors in the post-operative period. (NCT00587483)
Timeframe: Participants were followed from randomization until time to discharge from the hospital.
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Epinephrine | Norepinephrine | Vasopressin | |
| Amiodarone 300 mg | 1 | 0 | 2 |
| Lidocaine 1.5 mg /kg | 1 | 0 | 0 |
| Placebo (Saline) | 0 | 0 | 0 |
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
64 reviews available for amiodarone and Ventricular Fibrillation
| Article | Year |
|---|---|
Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Humans; M | 2022 |
Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudde | 2019 |
Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Emergency Medical Services; Humans; Intensive Care Units; Lidoca | 2017 |
Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia.
Topics: Amiodarone; Humans; Publication Bias; Pulse; Pyrimidinones; Randomized Controlled Trials as Topic; S | 2017 |
[Electrical storm: definition, prevalence, causes and prognostic implications].
Topics: Adrenergic beta-Antagonists; Amiodarone; Combined Modality Therapy; Defibrillators, Implantable; Hum | 2014 |
[Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone].
Topics: Amiodarone; Anti-Asthmatic Agents; Defibrillators; Humans; Injections, Intravenous; Potassium Channe | 2016 |
Amiodarone Versus Lidocaine for Pediatric Cardiac Arrest Due to Ventricular Arrhythmias: A Systematic Review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Combined Modality Therapy; Electric Countershock; Heart A | 2017 |
Should amiodarone or lidocaine be given to patients who arrest after cardiac surgery and fail to cardiovert from ventricular fibrillation?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benchmarking; Cardiac Surgical Procedures; Cardiopulmonary | 2008 |
Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; | 2009 |
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Humans; Infusions, Intravenous; Tachycardi | 2010 |
[Current role of amiodarone in antiarrhythmic therapy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Comple | 2010 |
Ventricular tachyarrhythmias (out-of-hospital cardiac arrests).
Topics: Amiodarone; Death, Sudden, Cardiac; Electric Countershock; Humans; Hypothermia, Induced; Lidocaine; | 2010 |
Amiodarone (Nexterone) injection for the treatment and prophylaxis of frequently recurring ventricular fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Humans; Randomized Controlled Trials as Topic; Ventricu | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2002 |
[Management of lethal ventricular arrhythmias after cardiac surgery].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiac Surgical Procedures; Cardiop | 2002 |
Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, | 2002 |
Amiodarone: an emergency medicine perspective.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Humans; Tachycardia, Ven | 2002 |
Strategies for reversing shock-resistant ventricular fibrillation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Cardiopulmonar | 2003 |
Cardiopulmonary Resuscitation Guidelines 2000 update: what's happened since?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electric Countershock; Emergency | 2003 |
Update on advanced life support and resuscitation techniques.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Clinical Trials as Topic; Electri | 2005 |
Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injur | 2005 |
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
Short QT syndrome: a case report and review of literature.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; ERG1 Pota | 2006 |
Clinical pharmacology of amiodarone.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; Heart Ventricles; Humans; | 1984 |
Amiodarone and post-MI patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Death, Sudden, Cardiac; | 1993 |
Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.
Topics: Amiodarone; Coronary Disease; Death, Sudden; Follow-Up Studies; Heart Failure; Humans; Sodium Channe | 1994 |
[Anti-arrhythmia agents in the therapy of ventricular arrhythmias in the post-CAST era].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Humans; Multicenter Studies as Topi | 1994 |
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P | 1994 |
Class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1994 |
Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?
Topics: Amiodarone; Animals; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrillators, Implantable; | 1993 |
Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Electrophysiology; Heart; Hemodynamics; Humans; Injecti | 1995 |
An overview of antiarrhythmic drug management of electrical storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Infusions, Intravenous; Lidoca | 1996 |
[Prognostic factors after sustained ventricular fibrillation or tachycardia. A multivariate study apropos of 160 cases].
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Amiodarone; Cardiac Pacin | 1996 |
Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Rate; Hemodynamics; Humans; Tachycardia, Ventricular; Vent | 1996 |
[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Death, Sudd | 1996 |
Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Catheter Ablation; Clinical Trials as Topic; Defibrillators | 1997 |
Intravenous amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Heart Conduction System; Hemod | 1997 |
Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic Disease; Cont | 1997 |
Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Heart Arrest; Humans; Randomized Co | 1997 |
Ventricular arrhythmias in the elderly.
Topics: Aged; Aged, 80 and over; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Coronar | 1998 |
Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Heart Failu | 1999 |
New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1999 |
Evidence-based analysis of amiodarone efficacy and safety.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden; Humans; Tachycardia, Ventric | 1999 |
Overview of trends in the control of cardiac arrhythmia: past and future.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electrocardiography, Ambulatory; Hu | 1999 |
Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1999 |
Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electric Countershock; Humans; Infusio | 1999 |
Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Multicenter Studies as Topi | 1999 |
Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators | 1999 |
Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Electroc | 1999 |
Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electroc | 1999 |
Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; M | 1999 |
Amiodarone: maximising survival benefit with empiric or guided therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Drug Administration Schedule; Empirici | 2000 |
Amiodarone: clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; D | 2000 |
[Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias].
Topics: Adrenergic beta-Antagonists; Amiodarone; Catheter Ablation; Electric Countershock; Humans; Tachycard | 2000 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Heart Failu | 1999 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardiography, Ambu | 1992 |
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; | 1990 |
Role of invasive electrophysiologic testing in the management of life-threatening ventricular arrhythmias.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Electrophysiology; Heart | 1988 |
Indications for the use of amiodarone: a personal perspective.
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Tachycardia; Ventricular Fibrillation | 1987 |
Practical follow-up guidelines for patients treated with amiodarone.
Topics: Amiodarone; Follow-Up Studies; Humans; Tachycardia; Ventricular Fibrillation | 1987 |
Pharmacologic therapy for survivors of sudden death based on programmed stimulation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden; Heart; Heart Arrest; | 1985 |
69 trials available for amiodarone and Ventricular Fibrillation
| Article | Year |
|---|---|
Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shock-Refractory Out-of-Hospital Cardiac Arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Humans; Lidocaine; Out-of- | 2022 |
Comparison of amiodarone and esmolol for prevention of reperfusion ventricular fibrillation in individuals undergoing heart valve or aortic surgery: a study protocol for a randomized controlled clinical trial.
Topics: Amiodarone; Heart Valves; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Reperf | 2023 |
Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Canada; Cardiopulmonary Resuscitation; Electrocardiography | 2018 |
Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Double-Blind Met | 2019 |
Effectiveness of VF induction with DC fibber versus conventional induction methods in patients on chronic amiodarone therapy.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Defibrillators, | 2013 |
Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Dose-Response | 2014 |
The effect of lidocaine and amiodarone on prevention of ventricular fibrillation in patients undergoing coronary artery bypass grafting.
Topics: Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combi | 2014 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Central Nervous Syst | 2016 |
Dantrolene versus amiodarone for cardiopulmonary resuscitation: a randomized, double-blinded experimental study.
Topics: Amiodarone; Animals; Blood Gas Analysis; Brain; Cardiopulmonary Resuscitation; Dantrolene; Disease M | 2017 |
Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Flow Cytometry; Human | 2009 |
No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Differentia | 2008 |
The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2008 |
Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiograp | 2009 |
Amiodarone for the prevention of reperfusion ventricular fibrillation.
Topics: Adult; Amiodarone; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Reperfusion; M | 2010 |
Prophylactic amiodarone versus lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamp.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Protocols; Coronary Artery Bypass; Female; Humans | 2009 |
Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electric Countershock; Emergenc | 2010 |
Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Death, Sudden, Cardiac; Defibrillators, Impla | 2011 |
Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aorta; Cardiac Surgical Procedures; Chi-Square Distributio | 2012 |
The end-of-study patient survey: methods influencing response rate in the AVID Trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bias; Data Collection; Defibrillators, Implantable; Endpoi | 2002 |
Transthoracic defibrillation of short-lasting ventricular fibrillation: a randomised trial for comparison of the efficacy of low-energy biphasic rectilinear and monophasic damped sine shocks.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Ele | 2002 |
Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT).
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiac | 2003 |
Shock on T versus direct current voltage for induction of ventricular fibrillation: a randomized prospective comparison.
Topics: Amiodarone; Defibrillators, Implantable; Digoxin; Electric Countershock; Female; Humans; Lidocaine; | 2004 |
Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Output; Case-Control Studies; Cohort Studies; Conf | 2004 |
Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Canada; Comorbidity; Coronary Artery Bypass; Death, Sudden | 2004 |
Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction.
Topics: Adaptation, Physiological; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Causality; Comorbidity; D | 2004 |
Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Coronary Ar | 2005 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; | 2006 |
Japanese randomized trial for investigation of a combined therapy of amiodarone and implantable cardioverter defibrillator in patients with ventricular tachycardia and fibrillation: the Nippon ICD Plus Pharmachologic Option Necessity study design.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Follow-U | 2006 |
[Implantable cardioverter defibrillator does not eliminate need for antiarrhythmic drugs in secondary prevention of life threatening ventricular arrhythmias. Results of OPTIC trial].
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Electric | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Dose-Response Relationship, Drug; Doub | 1995 |
Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 1995 |
Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: importance of beta-blockade.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Death, Sudden, Cardiac; Demography; Female; Follow-Up | 1995 |
Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA).
Topics: Aged; Amiodarone; Argentina; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Incidence; M | 1995 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
[Long-term results of amiodarone therapy in patients with sustained ventricular tachycardia or ventricular fibrillation for prevention of cardiac sudden death].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Death, Sudden, Cardiac; Female; Humans; Long-Term Care; | 1994 |
Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods.
Topics: Amiodarone; Cross-Over Studies; Defibrillators, Implantable; Humans; Prospective Studies; Quality of | 1995 |
Amiodarone as a first-line drug in the treatment of atrial fibrillation: the protagonist viewpoint.
Topics: Amiodarone; Coronary Disease; Death, Sudden; Follow-Up Studies; Heart Failure; Humans; Sodium Channe | 1994 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Chi-Square Distribution; Electrocardiography, Ambulatory; | 1993 |
Rehospitalization in surviving patients of out-of-hospital ventricular fibrillation (the CASCADE Study). Cardiac Arrest in Seattle: Conventional Amiodarone Drug Evaluation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Multivariate Analysis; | 1993 |
Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1994 |
Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Chi-Square Distribution; Electrocardiography, Ambulatory; | 1993 |
Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group.
Topics: Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Bradycardia; Cause of Death; Chi-Square Di | 1996 |
Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Female; Humans; Male; Metabolic Clearanc | 1996 |
[Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1996 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 1997 |
Measurement of the upper limit of vulnerability during defibrillator implantation can substitute defibrillation threshold measurement.
Topics: Adult; Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Creatine Kinase; Defibrillators, Implan | 1998 |
Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; De | 1999 |
Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Double-Blind Method; Electr | 1999 |
Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Hemodynamics; Humans; | 1999 |
Learning more about indications for implantable cardioverter-defibrillators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Hemodynamics; Humans; | 1999 |
In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Defibrillators, Implantable | 1999 |
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle | 2000 |
Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Double-Blind Method; Electric C | 2002 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
Clinical efficacy of amiodarone as an antiarrhythmic agent.
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Clinical Trials as Topic; Cornea; Drug Evaluation; He | 1976 |
Effects of chronic amiodarone therapy on defibrillation threshold.
Topics: Amiodarone; Defibrillators, Implantable; Electrodes, Implanted; Female; Follow-Up Studies; Humans; M | 1992 |
Efficacy and safety of amiodarone in treatment of refractory atrial and ventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans | 1992 |
A comparison of standard and high-dose regimens for the initiation of amiodarone therapy.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Drug Administration Schedule; Female; Heart Conduction | 1992 |
Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation.
Topics: Amiodarone; Cardiac Pacing, Artificial; Electric Countershock; Electrocardiography; Female; Humans; | 1991 |
Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator.
Topics: Amiodarone; Death, Sudden; Electric Countershock; Female; Follow-Up Studies; Humans; Male; Middle Ag | 1991 |
[Treatment of malignant ventricular tachyarrhythmia with amiodarone: comparison of empirical administration and administration guided by Holter or ventricular stimulation. Results of the parallel test].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cardiac Pacing, Artificial; Electrocardiography, Ambulat | 1991 |
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (the CASCADE study).
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Female; Heart Arrest; Humans; L | 1991 |
Development of congestive heart failure and alterations in left ventricular function in patients with sustained ventricular tachyarrhythmias treated with amiodarone.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Clinical Trials as Topic; Female; Heart; Heart Failure; | 1987 |
Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated | 1987 |
322 other studies available for amiodarone and Ventricular Fibrillation
| Article | Year |
|---|---|
Amiodarone or lidocaine, that is the question - Pharmacological therapy of refractory ventricular fibrillation associated with Brugada syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Brugada Syndrome; Humans; Lidocaine; Ventricular Fibrillation | 2021 |
Prophylactic amiodarone administration on ROSC after a successful first defibrillation.
Topics: Amiodarone; Cardiopulmonary Resuscitation; Electric Countershock; Humans; Ventricular Fibrillation | 2022 |
Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Bayes Theorem; Humans; Lidocaine; Out-of-Hospital Cardiac | 2022 |
Slow Ventricular Tachycardia on Amiodarone: An Adverse Complication or an Efficacy Outcome.
Topics: Accelerated Idioventricular Rhythm; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Humans; | 2022 |
Pharmacokinetics and pharmacodynamics of amiodarone in patients with hypertriglyceridemia: Two case reports.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Hypertriglyceridemia; Male; Middle Aged; Triglycer | 2022 |
Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Hospitals; Humans; Lidocai | 2023 |
Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry.
Topics: Adult; Amiodarone; Cardiopulmonary Resuscitation; Electric Countershock; Emergency Medical Services; | 2022 |
Amiodarone for the prevention of shocks and death in patients with implantable cardioverter-defibrillators: Hero or villain?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ven | 2023 |
Evaluation of the effectiveness of potassium chloride in the management of out-of hospital cardiac arrest by refractory ventricular fibrillation: Study protocol of the POTACREH study.
Topics: Amiodarone; Cardiopulmonary Resuscitation; Clinical Trials, Phase II as Topic; Electric Countershock | 2023 |
Intravenous bolus potassium: Appropriate indication in recurrent ventricular fibrillation.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Infusions, Intravenous; Injections, I | 2023 |
Regarding the Comparative Effectiveness of Lidocaine and Amiodarone for Treatment of In-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Heart Arrest; Hospitals; Humans; | 2023 |
Stable Ventricular Fibrillation: A Paradigm Rather Than Septal Shift?
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Lidocaine; Tachycardia, Ventricular; Ventricular Fibrillat | 2023 |
Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; | 2019 |
Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated With Prolonged Resuscitation.
Topics: Acidosis, Lactic; Advanced Cardiac Life Support; Amiodarone; Brain Damage, Chronic; Cardiopulmonary | 2020 |
No shocking updates for the lidocaine vs amiodarone in pediatric pVT/VF story.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Humans; Lidocaine; Ventricular Fibrillation | 2020 |
New Onset Recurrent Syncope Triggered by Fever.
Topics: Amiodarone; Coronary Angiography; Drug Therapy, Combination; Electric Countershock; Electrocardiogra | 2020 |
Ibutilide Reduces Ventricular Defibrillation Threshold and Organizes Ventricular Fibrillation Activation in Canine Heart Failure Model.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Arterial Pressure; Disease Models, A | 2020 |
Awake and aware with ongoing ventricular fibrillation during LVAD treatment: is it possible?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Heart Failure; Heart-Assist Devices; | 2020 |
Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cardiopulmonary Resuscita | 2020 |
Overdrive pacing of spiral waves in a model of human ventricular tissue.
Topics: Action Potentials; Amiodarone; Arrhythmias, Cardiac; Electrophysiology; Heart Conduction System; Hea | 2020 |
Prognostic benefits of prior amiodarone or β-blocker use before the onset of ventricular arrhythmia with hemodynamic collapse.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Hemodynamics; | 2021 |
Successful defibrillation using double sequence defibrillation: Case reports.
Topics: Adult; Amiodarone; Cardiopulmonary Resuscitation; Defibrillators; Electric Countershock; Electrocard | 2021 |
Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Coronary Artery Disease | 2022 |
Asymptomatic ventricular fibrillation in continuous flow left-ventricular assist device.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Ventricles; Heart-Assist Devi | 2021 |
Outcomes associated with lidocaine and amiodarone administration in pediatric in-hospital cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Heart Arrest; Hospitals; Humans; Lidocaine; Ventricular F | 2021 |
Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services | 2021 |
Fatal butane toxicity and delayed onset of refractory ventricular fibrillation.
Topics: Adult; Amiodarone; Butanes; Electric Countershock; Fatal Outcome; Humans; Male; Ventricular Fibrilla | 2017 |
Recurrent ventricular fibrillation associated with acute ingestion of hydrofluoric acid.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Calcium Gluconate; Fatal Outcome; Female; | 2018 |
2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Em
Topics: American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emerg | 2018 |
2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
Topics: American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Child | 2018 |
Preventing Ventricular Fibrillation in Patients With Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: Time to Consider Prophylactic Amiodarone Infusion.
Topics: Amiodarone; Aortic Valve; Aortic Valve Stenosis; Heart Valve Prosthesis; Humans; Hypertrophy, Left V | 2019 |
Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Female; Hear | 2019 |
Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Disease; Drug Evaluation; Drug Resistance; | 2019 |
The effects of amiodarone prophylaxis on cardiac dysrhythmia in acute aluminium phosphide poisoning.
Topics: Adolescent; Adult; Aluminum Compounds; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose | 2019 |
Outcomes associated with amiodarone and lidocaine for the treatment of adult in-hospital cardiac arrest with shock-refractory pulseless ventricular tachyarrhythmia.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Female; Heart Ar | 2020 |
Thyrotoxicosis-facilitated bridge to recovery with a continuous-flow left ventricular assist device.
Topics: Amiodarone; Cardiomyopathies; Heart-Assist Devices; Humans; Male; Thyrotoxicosis; Ventricular Fibril | 2013 |
Rhabdomyolysis during therapeutic hypothermia in a patient after successful cardio-pulmonary resuscitation.
Topics: Amiodarone; Cardiopulmonary Resuscitation; Drug Therapy, Combination; Electrocardiography; Epinephri | 2013 |
Safety of therapeutic hypothermia in post VF/VT cardiac arrest patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Arrest; Humans; Hypothermia, | 2013 |
Dronedarone and Captisol-enabled amiodarone in an experimental cardiac arrest.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiopulmonary Resuscitation; Disease | 2013 |
Protective effects of saffron (Crocus sativus) against lethal ventricular arrhythmias induced by heart reperfusion in rat: a potential anti-arrhythmic agent.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Crocus; Disease Models, Animal; Dose | 2013 |
Administration of amiodarone during resuscitation is associated with higher tumor necrosis factor-α levels in the early postarrest period in the swine model of ischemic ventricular fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Coronary Vessels; Diseas | 2013 |
Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disease Mode | 2013 |
Amiodarone inhibits apamin-sensitive potassium currents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Apamin; Calcium; Dose-Response Relationship, Drug; HEK293 Cells; | 2013 |
Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Child; Child, Preschool; Cohort Studies; Heart Arres | 2014 |
Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Dose-Response Relationship, | 2014 |
Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
Topics: Accelerated Idioventricular Rhythm; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomy | 2014 |
Adrenaline increases blood-brain-barrier permeability after haemorrhagic cardiac arrest in immature pigs.
Topics: Amiodarone; Animals; Blood-Brain Barrier; Capillary Permeability; Cardiopulmonary Resuscitation; Cer | 2014 |
Resuscitation with amiodarone increases survival after hemorrhage and ventricular fibrillation in pigs.
Topics: Amiodarone; Animals; Antidiuretic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Thyrotoxic cardiomyopathy with recurrent ventricular fibrillation and multi-organ failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Cardiomyopathies; Cardiopulmonary Resuscitat | 2014 |
Prolongation of a prolonged QT: a case of an undiagnosed congenital long QT syndrome.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Long QT Syndrome; Po | 2014 |
Renewed impact of lidocaine on refractory ventricular arrhythmias in the amiodarone era.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Female; Huma | 2014 |
Letter to the editor regarding manuscript "resuscitation outcomes consortium-amiodarone, lidocaine or placebo: rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trial".
Topics: Amiodarone; Cardiopulmonary Resuscitation; Female; Humans; Lidocaine; Male; Out-of-Hospital Cardiac | 2014 |
Regarding manuscript: "resuscitation outcomes consortium-amiodarone, lidocaine, or placebo study: rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trial".
Topics: Amiodarone; Cardiopulmonary Resuscitation; Female; Humans; Lidocaine; Male; Out-of-Hospital Cardiac | 2014 |
How long should resuscitative efforts be continued in adult out-of-hospital cardiac arrest?
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electric Countershock; Eme | 2015 |
Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Dronedarone; Drug Interactions; D | 2015 |
Proarrhythmic effect of 'Reverse Mode Switch' in a patient with dilated cardiomyopathy and drug-induced long QTc interval.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy; Cardiac Resynchronizati | 2015 |
Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Chagas Disease; Female; Humans; Male; Middle Aged; Parasi | 2015 |
Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation.
Topics: Amiodarone; Animals; Blood Pressure; Cardiopulmonary Resuscitation; Disease Models, Animal; Electric | 2015 |
Investigation of the antifibrillatory drug interactions between Amiodarone and Ibutilide in isolated, perfused Rabbit hearts.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Interactions; Heart; Lidocai | 2015 |
From Atrial Fibrillation to Ventricular Fibrillation and Back.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiopulmonary Resuscitation; Catheter Ablation; Combined M | 2015 |
Cardiac arrest in Antarctica--a successful outcome.
Topics: Amiodarone; Antarctic Regions; Cardiopulmonary Resuscitation; Electric Countershock; Epinephrine; He | 2016 |
ECMO Used in a Refractory Ventricular Tachycardia and Ventricular Fibrillation Patient: A National Case-Control Study.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Case-Control Studies; Comorbidity; Electric Counter | 2016 |
Intralipid in acute caffeine intoxication: a case report.
Topics: Advanced Cardiac Life Support; Amiodarone; Antidotes; Caffeine; Drug Overdose; Emulsions; Epinephrin | 2016 |
Long-term outcome and its predictors in giant cell myocarditis.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhy | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Emergency Medical Se | 2016 |
Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Female; Hospital Mo | 2016 |
Amiodarone administration for refractory ventricular fibrillation or pulseless ventricular tachycardia.
Topics: Administration, Intravenous; Adult; Amiodarone; Anti-Arrhythmia Agents; Emergency Nursing; Heart Arr | 2016 |
Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Digitalis Glycosides; Disease Models | 2017 |
Do not consider amiodarone, give it! Comment on antiarrhythmic drugs for shock‑refractory ventricular fibrillation or pulseless ventricular tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Tachycardia, Ventricular; Ventricular Fibrillation | 2016 |
In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival?
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Arrest; Humans; Lidocaine; Ventricular Fibrillation | 2017 |
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin- | 2017 |
The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation.
Topics: Amiodarone; Animals; Electric Countershock; Male; Oxazepines; Sodium Channel Blockers; Swine; Ventri | 2017 |
Comparison of the effects of sternal and tibial intraosseous administered resuscitative drugs on return of spontaneous circulation in a swine model of cardiac arrest.
Topics: Administration, Intravenous; Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitat | 2016 |
Defibrillation threshold testing in implantable cardioverter-defibrillators: might less be more than enough?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Differentia | 2008 |
[What is the best management in case of Rubigine ingestion?].
Topics: Adolescent; Amiodarone; Animals; Burns, Chemical; Calcium; Combined Modality Therapy; Dimethyl Sulfo | 2008 |
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2009 |
Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism?
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dy | 2009 |
A case of fatal caffeine poisoning.
Topics: Amiodarone; Anti-Arrhythmia Agents; Caffeine; Cardiopulmonary Resuscitation; Central Nervous System | 2010 |
Administration of amiodarone during resuscitation of ventricular arrhythmias.
Topics: Advanced Cardiac Life Support; Amiodarone; Anti-Arrhythmia Agents; Drug Administration Schedule; Dru | 2010 |
Amiodarone and reperfusion ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Myocardial Reperfusion; Myocardium; Ventricular Fibrilla | 2011 |
Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Disease Models, Animal; | 2010 |
Efficacy of amiodarone on refractory ventricular fibrillation resistant to lidocaine and cardioversion during weaning from cardiopulmonary bypass in aortic valve replacement for severe aortic stenosis with left ventricular hypertrophy.
Topics: Aged; Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Aortic Valve; Aortic Valve Stenosis; | 2010 |
Asymptomatic sustained ventricular fibrillation in a patient with left ventricular assist device.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Electric Countershock; Electrocardiography | 2011 |
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Confidence Intervals; Dose-Response Relati | 2011 |
[Successful use of intravenous amiodarone for refractory ventricular fibrillation just after releasing aortic cross-clamp].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Cardiopulmonary Bypass; Humans; Inj | 2010 |
A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Ther | 2011 |
Drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction: What does the crystal ball tell you?
Topics: Amiodarone; Anti-Arrhythmia Agents; Critical Care; Critical Illness; Electrocardiography; Female; Hu | 2011 |
Effects of chronic amiodarone on the electrical restitution in the human ventricle with reference to its antiarrhythmic efficacy.
Topics: Amiodarone; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Heart Ventric | 2011 |
The effects of acute amiodarone on short- and long-duration ventricular defibrillation threshold in canines.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Electric Countershock; Fo | 2011 |
Safety of nerve conduction studies in patients with implantable cardioverter-defibrillators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electromagnetic Phenomena; Fe | 2012 |
Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; CHO Cells; Cricetinae; Cricetulus; D | 2011 |
Proarrhythmic potential of amiodarone: an underestimated risk?
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated | 2012 |
Mechanical matters: consistent chest compressions help save patient.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Femal | 2011 |
Effect of amiodarone on dispersion of ventricular repolarization in a canine congestive heart failure model.
Topics: Amiodarone; Animals; Disease Models, Animal; Dogs; Female; Heart Failure; Male; Random Allocation; T | 2012 |
Effects of a novel amiodarone-like compound SAR114646A on the pig atrium and susceptibility to ventricular fibrillation in dogs and pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Elec | 2012 |
Chronic oral amiodarone but not dronedarone therapy increases ventricular defibrillation threshold during acute myocardial ischemia in a closed-chest animal model.
Topics: Acute Disease; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Coronary Occlusion | 2012 |
Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Ag | 2012 |
Incidence and severity of phlebitis in patients receiving peripherally infused amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization, P | 2012 |
Role of defibrillation threshold testing in the contemporary defibrillator patient population.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy Devices; Cardiomyopathy, | 2013 |
Amiodarone versus lidocaine for shock-resistant ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Heart Arrest; Hospitalization; Humans; Li | 2002 |
Implantable cardiac defibrillators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans; | 2002 |
Amiodarone versus lidocaine for shock-resistant ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Hospitalization; Humans; Lidocaine; Survival Rate; Time Factors; | 2002 |
Amiodarone versus lidocaine for shock-resistant ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Hospitalization; Humans; Lidocaine; Survi | 2002 |
Amiodarone versus lidocaine for shock-resistant ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Double-Blind Method; Excipients; Humans; Lidocaine; Placebos; Po | 2002 |
Life after a ventricular arrhythmia.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Follow-Up Studies; He | 2002 |
Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Death, Sudden, | 2002 |
Cardiac arrest related to coronary spasm in patients with variant angina: a three-case study.
Topics: Amiodarone; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Car | 2002 |
Incremental net benefit in randomized clinical trials with quality-adjusted survival.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Health Care Costs; Heart Arrest; Humans; | 2003 |
Clusters of ventricular fibrillation in a patient with an implantable cardioverter difibrillator treated with amiodarone.
Topics: Adult; Amiodarone; Angioplasty, Balloon, Coronary; Defibrillators, Implantable; Electrocardiography; | 2003 |
Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Disease Models, Animal; Dogs; Hypo | 2003 |
Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models | 2003 |
Successful resuscitation of a patient with electrical storm.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Electric Countershock; Female; | 2003 |
[Anticoagulation--control of heart rate--cardioversion. Therpeutic algorithm in ventricular tachycardia].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Combined Modality Therapy; | 2003 |
The role of amiodarone in the management of patients with cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Heart Arrest; Humans; Practice Gu | 2000 |
Effect of amiodarone on haemodynamics during cardiopulmonary resuscitation in a canine model of resistant ventricular fibrillation.
Topics: Amiodarone; Animals; Cardiopulmonary Resuscitation; Dogs; Drug Therapy, Combination; Electric Counte | 2003 |
Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiac Pacing, Artificial; Electrocardiogr | 2003 |
Electrical storm: case series and review of management.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Obesity Agents; B | 2003 |
Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone--an experimental study.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Differential Threshold; Electric Counte | 2004 |
Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Bradycardia; Electrocardiography | 2004 |
Randomized clinical trials: how long should they last?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Death, Sudden, Card | 2004 |
Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Prognosi | 2004 |
Salvage application of secondary blood cardioplegia in intractable ventricular fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Blood Gas Analysis; Cardiopulmonary Bypass; Dose-Response | 2004 |
Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Ve | 2005 |
A 25-year control of idiopathic ventricular fibrillation with electrophysiologic-guided antiarrhythmic drug therapy.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Follow-Up | 2004 |
Proarrhythmias and antiarrhythmias: two sides of the same coin.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing | 2005 |
Potential proarrhythmic effect of biventricular pacing: fact or myth?
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2005 |
QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Electric Countershock; Female; Heart Co | 2006 |
Letter from Konstantinos P. Letsas et al. - invited editorial comment.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Humans; Hypnotics and Sedatives; Long QT Synd | 2006 |
Clinical significance of the electrophysiologic study (EPS)-guided therapy for the secondary prevention of ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Catheter Ablation; Defibrilla | 2006 |
Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; | 2006 |
Colon ischaemia and necrosis as a complication of prolonged but successful CPR.
Topics: Adrenergic Agonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Colec | 2006 |
[Polymorphic ventricular tachycardia in acute myocardial infarction without ST elevation in a patient with thrombocytopenia].
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Angiography; Electrocardiography; | 2006 |
Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.
Topics: Adrenergic beta-Antagonists; Amiodarone; Cardiomyopathy, Dilated; Defibrillators, Implantable; Femal | 2006 |
Amiodarone and polymorphic ventricular tachycardia: to slow down or to accelerate the underlying rhythm?
Topics: Aged; Aged, 80 and over; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Atrial | 2006 |
[Time-frequency analysis of ventricular fibrillation and the effects of amiodarone].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Electric Countershock; Electrocardiography; Femal | 2007 |
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dronedarone; | 2007 |
[Long QT syndrome induced by cordaron and quinidine].
Topics: Amiodarone; Anemia, Hemolytic; Anti-Arrhythmia Agents; Female; Humans; Hypertension; Long QT Syndrom | 2007 |
Administration of amiodarone into the aortic root for persistent ventricular fibrillation after aortic valve replacement.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve; Aortic Valve Insufficiency; Cardiopulmonary | 2007 |
Antiarrhythmic induced electrical storm in Brugada syndrome: a case report.
Topics: Adrenergic beta-Agonists; Amiodarone; Anti-Arrhythmia Agents; Brugada Syndrome; Defibrillators, Impl | 2007 |
Varicella zoster induced cardiac dysfunction: a case report.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Chickenpox; Electrocardiography; Humans; Male; Seizures; | 2007 |
Cardiac transplantation in a patient with emotionally triggered implantable cardioverter defibrillator storms.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anxiety; Bradycardia; Defibrillators, Implantable; Electric | 2007 |
Cardioversion protocol for ventricular fibrillation: a more differentiated approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Electric Countershock; Heart Massag | 2007 |
Fatal outcome during anaesthesia induction in a patient with amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Androstanols; Anesthetics, Intravenous; Anti-Arrhythmia Agents; Etomidate; Fatal Outcome | 2008 |
ICD patients with elevated defibrillation threshold: clinical behavior and therapeutic alternatives.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 2008 |
[Sudden heart death in ventricular heart rhythm disorders: possibilities and limits of long-term therapy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Disopyramide; German | 1984 |
Serial electrophysiological studies in a young patient with recurrent ventricular fibrillation.
Topics: Adult; Amiodarone; Electrocardiography; Humans; Male; Quinidine; Recurrence; Ventricular Fibrillatio | 1981 |
Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation.
Topics: Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Rate; Heart | 1983 |
Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients.
Topics: Adolescent; Adult; Aged; Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Chemical and Drug Indu | 1982 |
Massive digoxin overdose: successful treatment with intravenous amiodarone.
Topics: Adult; Amiodarone; Benzofurans; Digoxin; Humans; Infusions, Parenteral; Male; Ventricular Fibrillati | 1983 |
Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia.
Topics: Administration, Oral; Aged; Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Electrocardiography | 1984 |
Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Dose-Response Relationship, Drug; Female | 1984 |
The correlation of serum amiodarone levels with abnormalities in the metabolism of thyroxine.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Female; Humans; Male; Middle Aged; Thyrotropin; | 1984 |
[Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Disopyramide; Drug Therapy, Combination; Electrocardiography | 1984 |
[Antiarrhythmic effect and side effects of amiodarone].
Topics: Adult; Aged; Airway Resistance; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cornea; Corneal Opaci | 1984 |
Plasma and red blood cell concentrations of amiodarone during chronic therapy.
Topics: Amiodarone; Anorexia; Benzofurans; Erectile Dysfunction; Erythrocytes; Humans; Male; Nausea; Saliva; | 1984 |
Amiodarone therapy for life threatening or refractory cardiac arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Kinetics; Ma | 1983 |
Electrophysiologic studies before and after myocardial revascularization in patients with life-threatening ventricular arrhythmias.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Coronary Artery Bypass; Digoxin; Electrophysiology; Fe | 1983 |
Ventricular arrhythmias: use of electrophysiologic studies.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; Electrophysiology; | 1983 |
Control of sudden recurrent arrhythmic deaths: role of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Electric Stimulation; Electro | 1983 |
Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Drug | 1983 |
Ventricular fibrillation in a conscious canine preparation of sudden coronary death--prevention by short- and long-term amiodarone administration.
Topics: Amiodarone; Animals; Benzofurans; Consciousness; Coronary Disease; Death, Sudden; Dogs; Electrocardi | 1983 |
Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing.
Topics: Amiodarone; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Mitral Valve Prolapse; Pacem | 1983 |
Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Anorexia; Ataxia; Benzofurans; Female; Heart Arrest; Humans; Lung Diseases; Male; | 1983 |
Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Femal | 1984 |
Effect of amiodarone on retrograde conduction and refractoriness of the His-Purkinje system in man.
Topics: Adult; Aged; Amiodarone; Benzofurans; Bundle of His; Electrocardiography; Heart Conduction System; H | 1984 |
Amiodarone: intravenous loading for rapid suppression of complex ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Benzofurans; Female; Heart Ventricles; Humans; Infusi | 1984 |
[Effect of previous administration of amiodarone on the early incidence of ventricular fibrillation during experimental myocardial ischemia].
Topics: Amiodarone; Animals; Benzofurans; Blood Pressure; Disease Models, Animal; Heart Rate; Male; Myocardi | 1984 |
Intravenous amiodarone in ventricular fibrillation.
Topics: Aged; Amiodarone; Benzofurans; Humans; Injections, Intravenous; Male; Middle Aged; Ventricular Fibri | 1981 |
Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.
Topics: Adult; Aged; Amiodarone; Benzofurans; Drug Evaluation; Electric Stimulation; Electrophysiology; Fema | 1981 |
Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Tachy | 1983 |
The efficacy of amiodarone for ventricular arrhythmias can be predicted with clinical electrophysiological studies.
Topics: Adult; Aged; Amiodarone; Benzofurans; Electrophysiology; Female; Heart Ventricles; Humans; Male; Mid | 1983 |
The efficacy of amiodarone for ventricular arrhythmias cannot be predicted with clinical electrophysiological studies.
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrophysiology; Heart Ventricles; Humans; Tachycar | 1983 |
Comparative antidysrhythmic profiles of bepridil, amiodarone and disopyramide in the guinea-pig and dog.
Topics: Aconitine; Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Bepridil; Disopyramide; Dogs; F | 1981 |
Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiog | 1982 |
[Effect of cordaron on the threshold of ventricular fibrillation in cats].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Cats; Female; Male; Myocardial Contraction | 1982 |
Amiodarone-induced ventricular fibrillation.
Topics: Amiodarone; Benzofurans; Bradycardia; Cardiac Pacing, Artificial; Electric Countershock; Electrocard | 1980 |
Failure of antiarrhythmic drugs to prevent experimental reperfusion ventricular fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Coronary Vessels; Dogs; Lidocaine; Ligation; Perfusion; | 1981 |
Intravenous amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Drug Costs; Humans; Infusions, Intrave | 1995 |
AVID necessity.
Topics: Amiodarone; Arrhythmias, Cardiac; Bias; Clinical Trials as Topic; Defibrillators, Implantable; Ethic | 1994 |
Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators.
Topics: Amiodarone; Atrial Fibrillation; Chemotherapy, Adjuvant; Defibrillators, Implantable; Electrocardiog | 1994 |
Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium; Electrocardiography; Heart; Homeostasis; Male; | 1995 |
Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Dose-Response Relationship, Drug; Female; Hu | 1995 |
Effects of antiarrhythmic drugs on epicardial defibrillation energy requirements and the rate of defibrillator discharges.
Topics: Amiodarone; Defibrillators, Implantable; Electrodes, Implanted; Female; Follow-Up Studies; Humans; M | 1993 |
Predictors of defibrillation energy requirements with nonepicardial lead systems.
Topics: Amiodarone; Defibrillators, Implantable; Electric Countershock; Electrodes, Implanted; Equipment Des | 1995 |
Clinical predictors of the defibrillation threshold with the unipolar implantable defibrillation system.
Topics: Amiodarone; Defibrillators, Implantable; Electric Countershock; Equipment Design; Female; Humans; Li | 1995 |
Comparison of cardiac electrophysiologic effects of experimental hypothyroidism and chronic oral amiodarone administration in dogs.
Topics: Amiodarone; Animals; Dogs; Electrocardiography; Electrophysiology; Female; Heart Conduction System; | 1994 |
Investigational status for intravenous amiodarone.
Topics: Amiodarone; Drugs, Investigational; Humans; Injections, Intravenous; Ventricular Fibrillation | 1994 |
Human experience with amiodarone in the embryonic period.
Topics: Abnormalities, Drug-Induced; Adult; Amiodarone; Female; Humans; Pregnancy; Pregnancy Complications, | 1994 |
[Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report].
Topics: Aged; Amiodarone; Bundle-Branch Block; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrilla | 1993 |
Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone.
Topics: Amiodarone; Electric Countershock; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; My | 1994 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death.
Topics: Adolescent; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Child; Death, Sudden, Cardiac; Electroc | 1993 |
Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Angiocardiography; Electrophysiolo | 1993 |
Oral amiodarone loading for the rapid treatment of frequent, refractory, sustained ventricular arrhythmias associated with coronary artery disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Coronary Disease; Drug Resistance; Female | 1993 |
The implantable defibrillator and antiarrhythmic drugs--competitive and complementary treatment for severe ventricular arrhythmia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Modality Therapy; Defibrillators, | 1993 |
Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study.
Topics: Amiodarone; Animals; Disease Models, Animal; Dogs; Electric Stimulation; Epinephrine; Female; Heart | 1994 |
Is there an effect of amiodarone on the defibrillation threshold?
Topics: Adult; Amiodarone; Cardiomyopathy, Dilated; Defibrillators, Implantable; Electrocardiography; Humans | 1993 |
Frequency-dependent electrophysiologic effects of amiodarone in humans.
Topics: Amiodarone; Cardiac Catheterization; Cardiac Pacing, Artificial; Cohort Studies; Follow-Up Studies; | 1993 |
[Ventricular fibrillation during stress test on a treadmill. Apropos of a case].
Topics: Amiodarone; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Electric Countershock; El | 1993 |
Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation.
Topics: Actuarial Analysis; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Follow- | 1993 |
Lowered threshold for ventricular fibrillation in amiodarone-treated pigs undergoing cardiopulmonary bypass and cardioplegic arrest with St. Thomas' cardioplegic solution.
Topics: Amiodarone; Animals; Bicarbonates; Calcium Chloride; Cardiac Pacing, Artificial; Cardioplegic Soluti | 1993 |
Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone.
Topics: Aged; Amiodarone; Humans; Infusions, Intravenous; Lung; Lung Diseases; Male; Phospholipids; Time Fac | 1993 |
Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Electrophysiology; Heart Arrest | 1995 |
A simulation study used to design the sequential monitoring plan for a clinical trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Computer Simulation; Decision Making; Defibrillators, Implantabl | 1995 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Deat | 1996 |
Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Male | 1996 |
Perioperative complications in combined aortic valve replacement and extraanatomic ascending-descending bypass.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aorta; Aorta, Thoracic; Aortic Coarctation; Aortic Valve; Aortic | 1996 |
Amiodarone for ventricular tachycardia after coronary artery bypass grafting.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; He | 1996 |
Optimal defibrillation strategy and follow-up of out-of-hospital cardiac arrest. The Belgian CPCR Study Group.
Topics: Amiodarone; Anti-Arrhythmia Agents; Belgium; Coronary Artery Bypass; Defibrillators, Implantable; El | 1996 |
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct | 1996 |
Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Disease Models, Anim | 1996 |
Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Diltiazem; Dogs; Electrocardi | 1996 |
[Predictive factors of induction of ventricular arrhythmia under amiodarone].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; | 1996 |
Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug A | 1997 |
Circadian modulation of ventricular tachycardia cycle length variability in ICD patients with dilated cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Circadian Rhythm; Defibrillators, | 1997 |
Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease?
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Chagas Cardiomyopathy; | 1997 |
Clinical predictors of defibrillation energy requirements.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Coronary Disease; Defi | 1997 |
[Etiologies of electric storm].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Electric Countershock; Female; Hemodyn | 1997 |
Effects of long-term amiodarone treatment on ventricular-fibrillation vulnerability and defibrillation efficacy in response to monophasic and biphasic shocks.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Electric Countershock; Heart Function Tests; Male; Rabb | 1997 |
Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Asia, Southeastern; Bundle-Branch Block; Death, Sudden, C | 1997 |
Clinical trials of implantable defibrillators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Artery Bypass; Coronary Disease; | 1997 |
Contrast-medium-induced ventricular fibrillation: arrhythmogenic mechanisms and the role of antiarrhythmic drugs in dogs.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Catheterization; Contrast Media; Cor | 1995 |
Increased dispersion of repolarization time determined by monophasic action potentials in two patients with familial idiopathic ventricular fibrillation.
Topics: Action Potentials; Adult; Amiodarone; Anti-Arrhythmia Agents; Electric Stimulation; Electrocardiogra | 1998 |
[Pharmacologic treatment for ventricular arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Coronary Disease; Heart Failure; Humans; Recur | 1997 |
Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Bl | 1998 |
Intravenous amiodarone for treating acute life threatening arrhythmias.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Humans; Injections, Intravenous; Tachycardia; Ven | 1998 |
Implantable cardioverter defibrillators--for whom?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Output, Low; Cause of Death; Coronary Artery Bypass; Dec | 1998 |
Successful resuscitation of ventricular fibrillation after low-dose amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Combined Modality Therapy; | 1998 |
[Further data on amiodarone. Evidence based therapy of cardiac arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Ventricular D | 1998 |
[Recommendations for the treatment of recurrent supraventricular tachycardia in infants].
Topics: Amiodarone; Anti-Arrhythmia Agents; Digoxin; Electric Countershock; Electrocardiography; Humans; Inf | 1998 |
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Child; Death, S | 1999 |
Ventricular arrhythmias and the use of antiarrhythmic drugs after cardiovascular surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Cardiovascular Surgical Procedures; Clinica | 1998 |
Effects of amiodarone on cardiac electrophysiology in right ventricular rapid pacing-induced heart failure dogs.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Electrophysiology; Female; Hea | 1998 |
Early proarrhythmia during intravenous amiodarone treatment.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart F | 1999 |
The effect of amiodarone on the ventricular fibrillation threshold.
Topics: Amiodarone; Animals; Blood Circulation; Blood Gas Analysis; Cardiopulmonary Resuscitation; Dose-Resp | 1999 |
A comparison of the antifibrillatory effects of desethylamiodarone to amiodarone in a swine model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Dru | 1999 |
Amiodarone reduces the prevalence of T wave alternans in a population with ventricular tachyarrhythmias.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Follow-Up Stud | 1999 |
Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac | 1999 |
Amiodarone in out-of-hospital cardiac arrest.
Topics: Amiodarone; Electric Countershock; Emergency Medical Services; Epinephrine; Heart Arrest; Humans; Su | 2000 |
Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant?
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Circadian Rhythm; Defibrillators, Implantable; Electrocar | 2000 |
[Apropos of amiodarone: both best and worst].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hyperthyroidism; Risk Factors | 2000 |
Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Butanes; Humans; Male; Recurrence; Resuscitation; Su | 2000 |
Frequency modulation within electrocardiograms during ventricular fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Electric Countershock; Electrocardiography; Femal | 2000 |
[Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Tachycardia, Ventricular; V | 2000 |
[Role of determination of QT dispersal intervals in anti-arrhythmia therapy].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Electrocar | 1999 |
Amiodarone: the AHA's new drug of choice for victims of ventricular arrhythmias.
Topics: American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Emergency Treatment; Guidelines as T | 2000 |
Serious arrhythmias in patients with apical hypertrophic cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmi | 2001 |
Amiodarone for ACLS: a critical evaluation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Contraindications; Drug Costs; Emergency Treatment; Humans; Unit | 2001 |
Absence of a morning peak in ventricular tachycardia and fibrillation events in nonischemic heart disease: analysis of therapies by implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Circadian Rhythm; Defibrillators, Implantable; Female | 2001 |
Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Diastole; In Vitro Techniques; Membr | 2002 |
Electrical storms in an ICD-recipient with 429 delivered appropriate shocks: therapeutic management with antiarrhythmic drug combination.
Topics: Aged; Amiodarone; Cardiomyopathy, Dilated; Defibrillators, Implantable; Electrocardiography; Follow- | 2002 |
Amiodarone used in successful resuscitation after near-fatal flecainide overdose.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Drug Overdose; Female; Flecainide | 2002 |
[The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillat | 2002 |
The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Electric Countershock; Research Design; Ventricul | 2002 |
[Amiodarone in the treatment of disorders of cardiac rhythm. results of six years of clinical experience (author's transl)].
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiac Complexes, Premature; Drug Evaluation; Humans | 1975 |
["Torsades de pointe" and reentry induced by anti-arrhythmia agents].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutte | 1978 |
Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart.
Topics: Amiodarone; Animals; Benzofurans; Coronary Disease; Coronary Vessels; Cyclic AMP; Depression, Chemic | 1979 |
[Amiodarone and propanolol: a dangerous combination?].
Topics: Amiodarone; Benzofurans; Drug Therapy, Combination; Heart Arrest; Humans; Propranolol; Ventricular F | 1979 |
["T'orsade de pointe" and amiodarone (author's transl)].
Topics: Amiodarone; Benzofurans; Female; Humans; Middle Aged; Mitral Valve Insufficiency; Syncope; Tachycard | 1978 |
Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle.
Topics: Action Potentials; Administration, Oral; Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Heart | 1992 |
Drug treatment of arrhythmias during cardiopulmonary resuscitation. A statement for the Advanced Life Support Working Party of the European Resuscitation Council.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Atropine; Bretylium Compounds; Calcium; Cardiopulmonary R | 1992 |
Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
Topics: Amiodarone; Cost-Benefit Analysis; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Cou | 1992 |
Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillators.
Topics: Acebutolol; Adolescent; Adult; Aged; Amiodarone; Combined Modality Therapy; Dose-Response Relationsh | 1992 |
Stabilization of cardiac rhythm in subsequently fatal ventricular tachycardia and fibrillation by calcitonin gene-related peptide.
Topics: Amiodarone; Calcitonin Gene-Related Peptide; Electric Countershock; Electrocardiography, Ambulatory; | 1992 |
Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cardiomyopathies; Coronary Disease; Death, Sudden, Cardi | 1991 |
Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Heart | 1991 |
Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, A | 1991 |
Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation.
Topics: Aged; Amiodarone; Death, Sudden, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Infu | 1991 |
Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Blood Pressure; Bretylium Compounds; Dogs; Drug Evaluatio | 1991 |
[Ventricular arrhythmia following thioridazine poisoning].
Topics: Amiodarone; Female; Humans; Middle Aged; Tachycardia; Thioridazine; Torsades de Pointes; Ventricular | 1991 |
Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts.
Topics: Amiodarone; Animals; Cardiac Output; Coronary Circulation; Doxorubicin; Drug Interactions; Male; Myo | 1990 |
Amiodarone--efficacy and late potentials during long-term therapy.
Topics: Amiodarone; Cardiomyopathy, Dilated; Coronary Disease; Electrocardiography; Humans; Prospective Stud | 1990 |
Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug | 1990 |
Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Follow-Up Studies; Heart; Humans; Life Tables; | 1990 |
Sudden cardiac death in a southeast Asian immigrant: clinical, electrophysiologic, and biopsy characteristics.
Topics: Adult; Amiodarone; Cambodia; Death, Sudden; Electrocardiography; Humans; Male; Refugees; United Stat | 1986 |
The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs.
Topics: Administration, Oral; Amiodarone; Animals; Dogs; Electric Countershock; Electrodes, Implanted; Infus | 1989 |
Acute electrophysiologic effects and antiarrhythmic/antifibrillatory activity of intravenous amiodarone in a chronic feline infarction model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cats; Chronic Disease; Electric Stimulation; Electrophy | 1989 |
[Ventricular fibrillation caused by the combined administration of amiodarone and quinidine].
Topics: Adolescent; Amiodarone; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography | 1989 |
Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation.
Topics: Amiodarone; Electrocardiography; Female; Heart Ventricles; Humans; Infusions, Intravenous; Male; Mid | 1989 |
Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden; Exercise Test; Humans; Male; Ventric | 1989 |
Intravenous amiodarone during prolonged resuscitation from cardiac arrest.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Female; Heart Arrest; Humans; Infusions, Intravenous; In | 1989 |
Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects.
Topics: Aged; Amiodarone; Electrophysiology; Female; Humans; Male; Middle Aged; Tachycardia, Supraventricula | 1989 |
Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac | 1989 |
Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease.
Topics: Amiodarone; Coronary Disease; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middl | 1989 |
Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Recurrenc | 1989 |
[Paradoxical response to amiodarone].
Topics: Adult; Amiodarone; Benzofurans; Female; Humans; Ventricular Fibrillation | 1986 |
Clinical experience with amiodarone for treatment of recurrent ventricular tachycardia and ventricular fibrillation.
Topics: Aged; Amiodarone; Benzofurans; Electrophysiology; Female; Heart; Humans; Lung; Male; Middle Aged; Ta | 1986 |
Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sotalol; Tachycardia; | 1988 |
Safety and efficacy of amiodarone. The low-dose perspective.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; E | 1988 |
Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis.
Topics: Adult; Amiodarone; Humans; Male; Thyroglobulin; Thyrotoxicosis; Ventricular Fibrillation | 1988 |
Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disea | 1988 |
Ventricular fibrillation in a patient with 'silent' mitral valve prolapse.
Topics: Adult; Amiodarone; Death, Sudden; Drug Therapy, Combination; Electrophysiology; Follow-Up Studies; H | 1988 |
Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Electrop | 1988 |
[Hyperkinetic ventricular arrhythmias in acute myocardial infarction: different etiopathogenetic mechanisms?].
Topics: Aged; Amiodarone; Electric Countershock; Electrocardiography; Female; Humans; Lidocaine; Male; Middl | 1987 |
[Remote results of the pharmacological treatment of patients with a high risk of sudden heart arrest in ventricular disorders of cardiac rhythm].
Topics: Adult; Aged; Amiodarone; Death, Sudden; Female; Heart Arrest; Humans; Male; Mexiletine; Middle Aged; | 1987 |
[Practical aspects of studies on amiodarone and desethylamiodarone levels in the sera of chronically treated patients].
Topics: Adolescent; Adult; Aged; Amiodarone; Humans; Middle Aged; Tachycardia, Supraventricular; Time Factor | 1987 |
Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide.
Topics: Aged; Amiodarone; Drug Interactions; Electrocardiography; Female; Heart; Heart Ventricles; Humans; I | 1987 |
Prognostic value of the changes in the mode of ventricular tachycardia induction during therapy with amiodarone or amiodarone and a class 1A antiarrhythmic agent.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Therapy, Combination; Ele | 1987 |
Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Female; Follow-Up Studie | 1987 |
Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cardiac Pacing, Artificial; Female; Follow-Up Studies; H | 1987 |
Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Electric Countershock; Electroc | 1987 |
Dissociation of electrophysiologic and pharmacologic stability during an abbreviated oral loading regimen of amiodarone.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Drug Administration Sc | 1987 |
Usefulness of electrophysiologic studies in predicting drug efficacy in patients receiving amiodarone.
Topics: Amiodarone; Cardiac Pacing, Artificial; Humans; Tachycardia; Ventricular Fibrillation | 1987 |
Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Ventricles; Humans; Male; Mexiletine; Middle | 1986 |
Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions.
Topics: Amiodarone; Animals; Benzofurans; Coronary Disease; Dogs; Electric Countershock; Electric Stimulatio | 1986 |
Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning.
Topics: Adult; Amiodarone; Antibody Specificity; Benzofurans; Digoxin; Female; Humans; Immunoglobulin Fab Fr | 1986 |
Effects of chronic amiodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation.
Topics: Aged; Amiodarone; Electric Stimulation; Electrophysiology; Female; Humans; Male; Middle Aged; Prospe | 1987 |
Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal.
Topics: Administration, Oral; Aged; Ambulatory Care; Amiodarone; Electrocardiography; Female; Humans; Male; | 1987 |
[Value and limitations of electropharmacological tests in the selection of anti-arrhythmic therapy in malignant ventricular tachyarrhythmia].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Electric Stimulation; Electrocardiography; Electrophysiol | 1985 |
Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity.
Topics: Aged; Amiodarone; Benzofurans; Coronary Disease; Death, Sudden; Drug Evaluation; Electrocardiography | 1986 |
Transient exacerbation followed by control of ventricular tachycardia with amiodarone.
Topics: Amiodarone; Benzofurans; Electrocardiography; Heart Ventricles; Humans; Male; Middle Aged; Tachycard | 1986 |
Amiodarone for refractory cardiac arrhythmias: 10-year study.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Coro | 1986 |
Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.
Topics: Adult; Aged; Amiodarone; Benzofurans; Coronary Disease; Electrophysiology; Female; Humans; Male; Mid | 1985 |
Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
Topics: Aged; Amiodarone; Analysis of Variance; Benzofurans; Death, Sudden; Female; Heart Arrest; Humans; Ma | 1985 |
Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone.
Topics: Adult; Aged; Ambulatory Care; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; El | 1985 |
Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effectiveness.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Cardiomyopathies; Coronary Disease; Drug Resi | 1985 |
[Effect of amiodarone on stimulatory convertibility and degeneration into ventricular fibrillation of induced ventricular tachycardias in the pig].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Female; Swine; Tachycardia; Ventricular Fi | 1985 |